Disorder of orbital region
MONDO:0002022A disease that involves the orbital region.
Also known as: disease of orbital region, disease or disorder of orbital region, disorder of eye region, disorder of orbital region, orbital region disease, orbital region disease or disorder, eye and adnexa disease, ophthalmological disorder
3161 clinical trials for this condition and its sub-types, 3 tagged with Disorder of orbital region itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Disorder of orbital region
-
Eye disorder 104 trials · 3,079 incl. sub-types
120 sub-types
- Retinal disorder 89 trials · 963 incl. sub-types Sub-types →
- Corneal disorder 46 trials · 465 incl. sub-types Sub-types →
- Lacrimal apparatus disorder 5 trials · 418 incl. sub-types Sub-types →
- Refractive error 82 trials · 400 incl. sub-types Sub-types →
- Ocular growth disorder 0 trials · 364 incl. sub-types Sub-types →
- Ocular vascular disorder 0 trials · 349 incl. sub-types Sub-types →
- Glaucoma 218 trials · 333 incl. sub-types Sub-types →
- Lens disorder 12 trials · 319 incl. sub-types Sub-types →
- Conjunctival disorder 1 trial · 314 incl. sub-types Sub-types →
- Uveal disorder 1 trial · 234 incl. sub-types Sub-types →
- Eye neoplasm 3 trials · 192 incl. sub-types Sub-types →
- Ocular hypertension 111 trials
- Eye degenerative disorder 0 trials · 97 incl. sub-types Sub-types →
- Autoimmune/inflammatory optic neuropathy 0 trials · 85 incl. sub-types Sub-types →
- Eye accommodation disease 6 trials · 69 incl. sub-types Sub-types →
- Eye infectious disorder 4 trials · 61 incl. sub-types Sub-types →
- Vitreous body disorder 0 trials · 50 incl. sub-types Sub-types →
- Eyelid disorder 4 trials · 47 incl. sub-types Sub-types →
- Gaucher disease 46 trials Sub-types →
- Hereditary optic neuropathy 1 trial · 30 incl. sub-types Sub-types →
- Optic neuritis 21 trials · 25 incl. sub-types Sub-types →
- Asthenopia 24 trials
- Ocular motor apraxia, Cogan type 23 trials
- Anterior segment dysgenesis 2 trials · 21 incl. sub-types Sub-types →
- Choroidal neovascularization 21 trials
- Eye allergy 2 trials · 20 incl. sub-types Sub-types →
- Neurotrophic keratopathy 17 trials
- Netherton syndrome 16 trials
- Mucopolysaccharidosis type 1 11 trials · 16 incl. sub-types Sub-types →
- Alagille syndrome 15 trials Sub-types →
- Ptosis 13 trials · 14 incl. sub-types Sub-types →
- Sandhoff disease 13 trials Sub-types →
- Tay-Sachs disease 13 trials Sub-types →
- GM1 gangliosidosis 12 trials Sub-types →
- Sturge-Weber syndrome 8 trials
- Isolated Pierre-Robin syndrome 8 trials Sub-types →
- Mucopolysaccharidosis type 6 8 trials Sub-types →
- Scotoma 7 trials
- Smith-Lemli-Opitz syndrome 6 trials
- Cerebrotendinous xanthomatosis 6 trials
- Coloboma 4 trials · 6 incl. sub-types Sub-types →
- Exophthalmos 6 trials
- Alpha-mannosidosis 5 trials Sub-types →
- Galactosemia 5 trials Sub-types →
- Niemann-Pick disease type A 4 trials
- Lamellar ichthyosis 4 trials Sub-types →
- Macular telangiectasia 1 trial · 4 incl. sub-types Sub-types →
- Piebaldism 4 trials
- Sjogren-Larsson syndrome 3 trials
- Isolated anophthalmia-microphthalmia syndrome 2 trials · 3 incl. sub-types Sub-types →
- Mucolipidosis type IV 3 trials
- Oculocerebrorenal syndrome 3 trials
- Pigment dispersion syndrome 3 trials
- Scleral disorder 1 trial · 3 incl. sub-types Sub-types →
- Toxic maculopathy due to antimalarial drugs 3 trials
- Galactosialidosis 2 trials
- Nail-patella syndrome 2 trials
- Rhizomelic chondrodysplasia punctata 2 trials Sub-types →
- Vernal keratoconjunctivitis 2 trials
- Visual snow syndrome 2 trials
- Gardner syndrome 1 trial
- Tietz syndrome 1 trial
- X-linked cone dysfunction syndrome with myopia 1 trial
- Acute zonal occult outer retinopathy 1 trial
- Atopic keratoconjunctivitis 1 trial
- Ocular hypotension 1 trial Sub-types →
- 9q33.3q34.11 microdeletion syndrome 0 trials
- Axenfeld anomaly 0 trials
- Cogan syndrome 0 trials
- Ehlers-Danlos syndrome, kyphoscoliotic type 1 0 trials
- Foster-Kennedy syndrome 0 trials
- IRVAN syndrome 0 trials
- IgG4-related ophthalmic disorder 0 trials Sub-types →
- Ito hypomelanosis 0 trials
- LTBP2-related ocular dysgenesis 0 trials Sub-types →
- Lowry-MacLean syndrome 0 trials
- Marshall syndrome 0 trials
- Peters plus syndrome 0 trials
- Rothmund-Thomson syndrome type 2 0 trials
- SHORT syndrome 0 trials
- Spasmus nutans 0 trials
- Acute annular outer retinopathy 0 trials
- Anterior dislocation of lens 0 trials
- Anterior segment developmental abnormality with extraocular manifestations 0 trials
- Blindness - scoliosis - arachnodactyly syndrome 0 trials
- Chondroectodermal dysplasia with night blindness 0 trials
- Congenital optic disk excavation 0 trials
- Dyssegmental dysplasia-glaucoma syndrome 0 trials
- Ectodermal dysplasia-blindness syndrome 0 trials
- Essential strabismus 0 trials
- Extensive peripapillary myelinated nerve fibers 0 trials
- Familial cavitary optic disk anomaly 0 trials
- Fatty acyl-CoA reductase 1 deficiency 0 trials
- Glaucoma-sleep apnea syndrome 0 trials
- Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome 0 trials
- Hereditary hyperferritinemia with congenital cataracts 0 trials
- Idiopathic linear interstitial keratitis 0 trials
- Isolated angioid streaks 0 trials
- Isolated ankyloblepharon filiforme adnatum 0 trials
- Isolated blepharochalasis 0 trials
- Keratomalacia 0 trials
- Luxation of globe 0 trials
- Megalocornea-intellectual disability syndrome 0 trials
- Mevalonic aciduria 0 trials
- Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome 0 trials
- Microcornea-corectopia-macular hypoplasia syndrome 0 trials
- Microcornea-glaucoma-absent frontal sinuses syndrome 0 trials
- Multiple evanescent white dot syndrome 0 trials
- Neuroocular syndrome 0 trials Sub-types →
- Ocular cystinosis 0 trials
- Ocular dysgenesis caused by defects in PAX6 regulation 0 trials
- Ocular siderosis 0 trials
- Oculodentodigital dysplasia 0 trials Sub-types →
- Ophthalmia nodosa 0 trials
- Phakomatosis pigmentovascularis 0 trials Sub-types →
- Punctate inner choroidopathy 0 trials
- Red color blindness 0 trials
- Stellate multiform amelanotic choroidopathy 0 trials
- Syndromic recessive X-linked ichthyosis 0 trials
- Tyrosinemia type II 0 trials
-
Eye adnexa disorder 0 trials · 603 incl. sub-types
6 sub-types
- Lacrimal apparatus disorder 5 trials · 418 incl. sub-types Sub-types →
- Conjunctival disorder 1 trial · 314 incl. sub-types Sub-types →
- Disease of orbital part of eye adnexa 2 trials · 79 incl. sub-types Sub-types →
- Eyelid disorder 4 trials · 47 incl. sub-types Sub-types →
- Myopathy of extraocular muscle 1 trial · 5 incl. sub-types Sub-types →
- Ocular adnexal lymphoma 4 trials
-
Orbit neoplasm 0 trials · 2 incl. sub-types
2 sub-types
- Orbital cancer 0 trials · 2 incl. sub-types Sub-types →
- Intraorbital meningioma 0 trials
-
Orbital dermoid cyst 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 569 trials in this tab.
-
Can a One-Time gene edit stop glaucoma in its tracks?
Cure PausedThis trial tests a new gene-editing therapy called BD113vVLP for people with primary open-angle glaucoma caused by a specific genetic mutation (MYOC). The therapy is injected into the eye and aims to disable the faulty gene that leads to high eye pressure. The study will evaluate…
Sponsor: Shanghai BDgene Co., Ltd. • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Can a single injection save sight in a rare retinal disease?
Cure OngoingThis early-stage trial is testing whether a gene therapy called NGGT001, injected under the retina, is safe and tolerable for people with Bietti's crystalline dystrophy, a rare inherited condition that causes progressive vision loss. The study enrolls about 11 adults with a confi…
Early phase 1 • Sponsor: Xiamen Ophthalmology Center Affiliated to Xiamen University • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Can a single injection restore sight in a rare genetic eye disease?
Cure OngoingThis trial tests an experimental gene therapy called NGGT001 for people with Bietti Crystalline Dystrophy, a rare inherited condition that causes progressive vision loss. The therapy is delivered as a single injection under the retina, aiming to replace a faulty gene with a worki…
Phase 1/2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
Can a single injection restore sight in a rare childhood blindness?
Cure OngoingThis trial tests a gene therapy called ATSN-101, given as a one-time injection under the retina, for people with Leber congenital amaurosis caused by GUCY2D gene mutations. The goal is to see if the treatment is safe and can improve vision. Participants receive the therapy in one…
Phase 1/2 • Sponsor: Atsena Therapeutics Inc. • Aim: Cure
Last updated Aug 05, 2026 00:00 UTC
-
Can a single eye injection restore sight in genetic blindness?
Cure OngoingThis trial tests an experimental gene therapy called OCU400 in people with retinitis pigmentosa or Leber congenital amaurosis, which are inherited conditions that cause progressive vision loss and can lead to blindness. The therapy is given as a single injection into the eye, wit…
Phase 1/2 • Sponsor: Ocugen • Aim: Cure
Last updated Aug 02, 2026 00:00 UTC
-
Modified vitamin a pill tested against inherited blindness
Disease control OngoingResearchers are testing whether a daily pill called ALK-001 can slow the progression of Stargardt disease, a rare inherited condition that causes vision loss in children and young adults. The trial enrolls people aged 8 and older who have a clinical diagnosis of Stargardt disease…
Phase 2 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Vitamin a derivative eyed to halt inherited blindness
Disease control OngoingResearchers are testing a daily oral drug called ALK-001 in people aged 8 to 70 with Stargardt disease, an inherited condition that causes progressive vision loss. The trial compares ALK-001 to a placebo over 24 months to see if the drug is safe and can slow damage to the retina.…
Phase 2 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Can special glasses stop Kids' eyesight from getting worse?
Disease control OngoingThis study tests whether new spectacle lenses can safely slow the progression of myopia (nearsightedness) in children. About 249 kids will wear either the novel lenses or standard single vision glasses for 36 months. Researchers will measure changes in eye length and prescription…
Sponsor: HOYA Lens Thailand LTD. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Higher-Dose eye injection shows promise for two leading causes of vision loss
Disease control OngoingThis study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks to people with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME). The goal is to see if this dosing schedule is safe and works well for those who have a…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New gene therapy targets Parkinson's in patients with specific gene flaw
Disease control OngoingThis study tests a new gene therapy called LY3884961 in 32 people with moderate to severe Parkinson's disease who have a specific genetic change (GBA1 mutation). The treatment is given as a single injection into the fluid around the brain and spinal cord. The main goal is to chec…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New eye injection aims to slow genetic blindness
Disease control OngoingThis study tests a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that damages the optic nerve (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose,…
Phase 1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a daily injection save your sight? new trial for dry AMD
Disease control OngoingThis phase 3 trial tests whether a daily injection of elamipretide can slow vision loss in people with dry age-related macular degeneration (AMD). About 313 adults aged 55 and older with early dry AMD will receive either the drug or a placebo for 96 weeks. The main goal is to see…
Phase 3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can special lenses plus eye drops stop Kids' myopia from getting worse?
Disease control OngoingThis study tests whether combining special glasses (that create optical defocus) with low-dose atropine eye drops can better control myopia (nearsightedness) in children aged 7 to 12. Over 18 months, researchers will measure changes in eye prescription and eye length. The goal is…
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New eye injection aims to halt diabetic vision loss
Disease control OngoingThis study tests an experimental drug called BI 764524, given as an eye injection, in 190 adults with moderate to severe diabetic retinopathy. Participants receive different numbers of injections over a year, and doctors compare eye damage improvements against a sham procedure or…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Robot aims to bust clots in the eye to save sight
Disease control OngoingRetinal vein occlusion happens when a clot blocks a vein in the eye, leading to vision loss. Current treatments manage the fluid buildup but do not remove the clot. This trial tests whether a robot can safely guide a tiny needle into the blocked vein to inject tPA, a clot-dissolv…
Sponsor: University of Oxford • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail targets rare eye cancer
Disease control OngoingThis phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and res…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Eye implant takes aim at diabetic macular edema
Disease control OngoingResearchers are testing two doses of an experimental eye implant called EC-104 against the standard Ozurdex implant in adults with diabetic macular edema. The trial enrolls people whose swelling did not improve enough with anti-VEGF injections but who have tolerated steroid eye t…
Phase 1/2 • Sponsor: Eclipse Life Sciences, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New gene therapy aims to fix immune system in rare disease
Disease control By invitation onlyThis study tests a new gene therapy for people with chronic granulomatous disease (CGD), a genetic disorder that weakens the immune system and makes them prone to serious infections. The treatment takes the patient's own blood stem cells, adds a missing gene in the lab, and puts …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New eye drops aim to boost blood flow in diabetic retinopathy and glaucoma
Disease control OngoingThis early study tests whether QLS-111 eye drops can improve blood flow to the back of the eye in people with non-proliferative diabetic retinopathy or certain types of glaucoma. Fourteen participants will use the drops twice daily for two weeks. The main goal is to measure chang…
Phase 2 • Sponsor: Qlaris Bio, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New laser method could make glaucoma treatment easier
Disease control By invitation onlyThis study tests if a new, automated laser treatment (DSLT) works as well as the standard laser treatment (SLT) for lowering eye pressure in people with open-angle glaucoma. About 51 adults will receive one of the two treatments and be followed for 12 months. The goal is to see i…
Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Eye drops face off to halt Kids' worsening nearsightedness
Disease control OngoingResearchers compare two strengths of atropine eye drops, 0.05% and 0.5%, in Dutch children aged 6 to 11 with progressive nearsightedness. About 550 children use the drops for three years, then researchers follow them for two more years. The goal is to see which strength better sl…
Phase 3 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Cornea transplant showdown: which surgery gives sharper sight?
Disease control OngoingThis study compares two types of cornea transplant surgery—DSAEK and DMEK—in 220 adults with corneal swelling or Fuchs' dystrophy. The goal is to see which procedure leads to better vision and patient satisfaction one year after surgery. Participants will be randomly assigned to …
Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New implant could replace eye drops after corneal surgery
Disease control By invitation onlyThis study tests whether a tiny steroid-releasing implant (Dextenza) placed in the tear duct works as well as standard steroid eye drops after corneal crosslinking surgery for keratoconus. About 20 people aged 13 and older with progressive keratoconus will receive either the impl…
Phase 1/2 • Sponsor: Maanasa Indaram, MD • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New eye injection aims to slow vision loss from Age-Related macular degeneration
Disease control OngoingThis study tests the safety of a drug called ASP3021 (avacincaptad pegol) for people in Japan with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Twenty participants will receive monthly injections into the affected eye for 12 mo…
Phase 4 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Myopia glasses may keep working even after kids take them off
Disease control OngoingResearchers are studying whether the benefit of a special spectacle lens for slowing nearsightedness lasts after children stop wearing it. The trial follows 91 children who took part in an earlier three-year study, where some wore the innovative lenses and others wore regular sin…
Sponsor: Essilor International • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Gene therapy shot could end frequent eye injections for wet AMD
Disease control OngoingThis early-stage trial tests a one-time gene therapy injection (NG101) for wet age-related macular degeneration. The therapy uses a harmless virus to deliver a gene that makes a drug inside the eye, aiming to reduce the need for repeated anti-VEGF injections. About 20 adults aged…
Phase 1/2 • Sponsor: Elisigen, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could skipping Face-Down recovery be safe for macular hole surgery?
Disease control OngoingThis trial tests whether people with large macular holes (over 400 micrometres) can heal without the usual face-down positioning after surgery. All participants undergo a procedure called inverted flap vitrectomy with gas tamponade, and half are asked to avoid face-down posturing…
Sponsor: Lahore General Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New weekly shot aims to tame Sjögren's Flare-Ups
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in 180 adults with moderate to severe Sjögren's disease. Participants receive either the drug or a placebo as a weekly injection under the skin for 24 weeks. The goal is to see if the drug can reduce overall disease activity …
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Donated corneal tissue eyed as fix for Post-LASIK farsightedness
Disease control By invitation onlyMany people who have LASIK still need glasses for leftover farsightedness. Researchers are testing whether implanting a thin piece of donated corneal tissue, shaped by ReLex Smile surgery, can improve vision. The trial enrolls 60 young adults with residual farsightedness after LA…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug aims to calm swollen eyes in thyroid disease patients
Disease control OngoingThis study tests an experimental drug called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the drug can reduce eye bulging over 24 weeks. Participants receive the drug …
Phase 1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for kidney transplant patients: extended drug trial targets rejection
Disease control By invitation onlyThis study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through bio…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a diabetes drug protect your eyes? 5-Year trial seeks answers
Disease control OngoingThis study looks at whether semaglutide, a medicine for type 2 diabetes, can slow or prevent diabetic eye disease over 5 years. About 1500 adults with type 2 diabetes will receive either semaglutide or a placebo injection once a week, in addition to their usual diabetes medicatio…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for thyroid eye disease: phase 3 drug trial launches in china
Disease control OngoingThis study tests a new drug called ZL-1109 for people with moderate to severe thyroid eye disease, a condition that causes eye bulging and discomfort. About 99 Chinese adults will receive either the drug or a placebo to see if it safely reduces eye bulging by at least 2 millimete…
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Eye size may reveal which kids benefit most from myopia lenses
Disease control OngoingThis study tests whether pupil size changes can predict how well peripheral defocus spectacle lenses slow myopia progression in children. Researchers will measure pupil responses and track eye growth over 24 months in 14 kids with progressive myopia. The goal is to see if a simpl…
Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Immune cell reprogramming offers hope for stubborn arthritis and Sjogren's
Disease control OngoingThis early-phase study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjogren's disease. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Contact lens showdown: which lens slows Kids' nearsightedness best?
Disease control OngoingThis study compares two special contact lenses (MiSight 1 Day and Abiliti 1-Day) to see which one better slows the worsening of nearsightedness in Chinese children aged 6-12 living in New Zealand. Each child will wear a different lens in each eye for 6 months. The goal is to find…
Phase 3 • Sponsor: Aston University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New eye drug could mean fewer shots for Diabetes-Related vision loss
Disease control OngoingThis study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug could slash injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 participants will receive either EYP-1901 or the standard drug aflibercept. The goal is to see if EYP-1901 can maintain or…
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug aims to cut injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 people with wet AMD will receive either EYP-1901 or standard aflibercept injections over 2 years. The main goal is to see …
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug could cut injection frequency for Diabetes-Related vision loss
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug shows promise for Diabetes-Related vision loss
Disease control OngoingThis early-stage study tests a new drug, RO7497372, given as an eye injection for people with diabetic macular edema (DME), a condition that causes vision loss. The trial involves 151 participants and aims to check the drug's safety, how long it stays in the eye and blood, and it…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New eye lens could let you focus without glasses after cataract surgery
Disease control OngoingThis study is testing a new type of intraocular lens (IOL) that can be adjusted after cataract surgery using laser energy, potentially allowing the eye to focus at different distances. Researchers will enroll 85 adults with cataracts in both eyes to check safety and how well the …
Sponsor: Alcon Research • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control PausedThis phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
A daily eye drop might slow childhood nearsightedness. a trial puts it to the test.
Disease control OngoingThis phase 3 trial tests whether an experimental eye drop called CTO0308 can slow the progression of myopia, or nearsightedness, in children aged 5 to 12. Participants receive either the active drop or a placebo once daily in each eye for 12 months. Researchers measure changes in…
Phase 3 • Sponsor: Taejoon Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Eye implant could replace monthly shots for blinding disease
Disease control OngoingThis study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New fluid lens could sharpen vision after cataract surgery
Disease control OngoingThis study tests a new type of lens implant for people having cataract surgery. The lens uses fluid to adjust focus, aiming to improve vision compared to a standard fixed-focus lens. About 175 participants will receive either the new lens or a standard one, and their vision and a…
Sponsor: Alcon Research • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Gene therapy targets second eye in rare blindness disorder
Disease control OngoingThis study tests a gene therapy called botaretigene sparoparvovec in the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. The 24 participants previously received the therapy in one eye and are now being followed for safety and …
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Gene therapy shows promise for rare blindness disease
Disease control OngoingThis study is a follow-up to a Phase 3 trial testing a gene therapy called AAV5-hRKp.RPGR for people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. The treatment aims to slow or stop vision decline by delivering a working copy of the RPGR gene …
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug nipocalimab tested in 655 Sjogren's patients in major trial
Disease control OngoingThis phase 3 trial tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease. About 655 participants receive either nipocalimab or a placebo, along with standard care, for 48 weeks. The main goal is to see if the drug improve…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental gene therapy aims to halt vision loss in rare eye disease
Disease control OngoingThis Phase 3 study tests a gene therapy called AAV5-hRKp.RPGR in 4 Japanese people with X-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. The therapy is injected into the eye to deliver a working copy of the RPGR gene. The main goal is to che…
Phase 3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a tiny implant replace monthly eye shots for wet AMD?
Disease control OngoingThis study tests an experimental implant (AR-14034) that slowly releases medication inside the eye to treat wet age-related macular degeneration (AMD). The goal is to see if it is safe and can work as well as or better than standard anti-VEGF injections, which require frequent do…
Phase 1/2 • Sponsor: Alcon Research • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a disc made from donated tissue ease severe dry eye?
Disease control CancelledThis Phase 3 trial tests whether a disc made from donated human amnion membrane can help people with moderate to severe dry eye disease. The disc is placed on the eye and compared to standard care like lubricating drops and a bandage lens. The study will enroll 40 adults who have…
Phase 4 • Sponsor: Cellution Biologics • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a One-Time gene injection slow inherited blindness?
Disease control OngoingThis study follows patients with Stargardt's macular degeneration, an inherited eye disease that causes progressive vision loss, who previously received an experimental gene therapy called SAR422459. The goal is to check the long-term safety and tolerability of the treatment and …
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a blood thinner boost vision after retinal detachment surgery?
Disease control OngoingThis trial tests whether adding enoxaparin (Clexane) to the fluid used during vitrectomy surgery can improve vision in people with retinal detachment complicated by proliferative vitreoretinopathy (PVR), a condition where scar-like tissue forms on the retina. About 60 adults aged…
Sponsor: Lahore General Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Double surgery combo may help glaucoma patients see better outcomes
Disease control By invitation onlyThis study reviews 100 patients with open-angle glaucoma who had two minimally invasive surgeries (Hydrus microstent and iTrack canaloplasty) along with cataract surgery. Researchers want to see if this combination lowers eye pressure and reduces the need for glaucoma medications…
Sponsor: University of Utah • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New eye drug trial focuses on black, hispanic, and native american patients
Disease control OngoingThis study tests a drug called faricimab (VABYSMO) in 218 people with diabetic macular edema who have not been treated before. The participants are Black/African American, Hispanic/Latino American, Native American/Alaska Native/Native Hawaiian/Pacific Islander, or Asian Indian. T…
Phase 4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental drug combo tested for rare, deadly castleman disease
Disease control OngoingThis study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new eye drop tame uveitis inflammation without steroids?
Disease control OngoingThis trial tests an experimental eye drop called VVN461 in people with non-infectious anterior uveitis, a condition causing inflammation inside the front of the eye. Participants receive either VVN461 or a standard steroid eye drop for four weeks. The study measures whether VVN46…
Phase 3 • Sponsor: VivaVision Biotech, Inc • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Modular eye lens shows promise for clearer sight at all distances
Disease control Details not publishedThis study tested a new modular lens called the AVL200, implanted during cataract surgery to also correct presbyopia (age-related blurry near vision). Nine people received the lens and were followed for one year. Researchers measured how well they could see at different distances…
Sponsor: [Redacted] • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New glasses could slow Kids' worsening eyesight
Disease control OngoingThis study tests whether Essilor Stellest spectacle lenses can slow the progression of myopia (nearsightedness) in children and teens aged 6 to 16. One hundred fifty participants will wear the lenses for at least 12 hours a day over 24 months. Researchers will measure changes in …
Sponsor: Essilor International • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New eye drug EYE103 takes on standard treatment for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a common cause of vision loss in diabetes. About 1,054 participants receive injections into the eye every 4 weeks for a year, then l…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Rapamycin drug tested for rare castleman disease
Disease control OngoingThis phase 2 study tests the drug sirolimus (rapamycin) in 7 people with idiopathic multicentric Castleman disease who have not improved with standard therapy. The goal is to see if sirolimus can improve symptoms like fatigue, fever, and night sweats, and shrink enlarged lymph no…
Phase 2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a condition that causes vision loss in diabetes. About 984 participants will receive injections into the eye every 4 weeks for a yea…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a One-Time gene therapy preserve sight for years? a 15-Year study aims to find out
Disease control OngoingThis study follows people who previously received a one-time gene therapy injection for a rare inherited eye disease caused by RPE65 mutations. Researchers will test vision and light sensitivity over up to 15 years to see how well the treatment holds up. The goal is to understand…
Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new pill tame eye inflammation when others fail?
Disease control OngoingThis study tests whether upadacitinib, a drug currently used for other inflammatory conditions, can help people with uveitis—an eye disease causing inflammation—that hasn't responded to standard treatments. Participants aged 12 to 70 will take a 15 mg extended-release tablet dail…
Phase 4 • Sponsor: Tianjin Medical University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Gene therapy shot could end need for repeated eye needles in diabetes
Disease control OngoingThis phase 2 trial tests RGX-314, a gene therapy given as a single injection into the eye, for people with diabetic retinopathy. The goal is to see if it can improve vision and reduce the need for frequent anti-VEGF injections. About 139 adults with diabetes-related eye damage ar…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Sjögren's drug ianalumab tested for Long-Term safety in 600-Patient trial
Disease control OngoingThis phase 3 study tests the long-term safety of ianalumab in 612 people with Sjögren's syndrome who already completed a year of treatment in earlier trials. Participants receive ianalumab or placebo injections for up to several more years. The goal is to see if the drug remains …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New shot could ease bulging eyes in thyroid disease
Disease control OngoingThis Phase 3 trial tests an investigational drug called VRDN-003 for active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The study involves 132 adults with moderate to severe symptoms. Participants receive either VRDN-003 or a placebo as a sh…
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control OngoingThis phase 3 trial tests an investigational drug called VRDN-003 in 204 people with chronic thyroid eye disease (TED). The drug is given as a shot under the skin and aims to reduce eye bulging and other symptoms. Participants are randomly assigned to receive either VRDN-003 or a …
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
A new strategy to slow nearsightedness in kids: switching between two proven treatments
Disease control OngoingThis trial tests whether alternating two common myopia treatments—nightly ortho-k contact lenses and low-dose atropine eye drops—can slow the progression of nearsightedness in children and teens more effectively than using ortho-k lenses alone. The study will enroll 112 participa…
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Light-Activated dye could save sight from severe eye infections
Disease control OngoingThis study tests whether a light-activated dye called rose Bengal, combined with antibiotics and steroids, can improve vision in people with severe bacterial eye infections. About 60 adults with corneal ulcers and vision loss will receive either the dye treatment or a sham proced…
Phase 3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New laser could ease glaucoma without drops
Disease control OngoingThis study tests a new laser procedure called Direct Selective Laser Trabeculoplasty (DSLT) in 40 ethnic Chinese patients with glaucoma or high eye pressure. The laser aims to improve fluid drainage in the eye and reduce pressure. Researchers will check if the treatment is safe a…
Sponsor: BelkinVision • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New eye injection aims to halt vision loss in dry AMD
Disease control OngoingThis early-stage trial is testing a new drug called VOY-101 for people with advanced dry age-related macular degeneration (AMD) and geographic atrophy, a condition that causes blind spots. The drug is injected into the eye and aims to slow damage to the retina and preserve vision…
Phase 1/2 • Sponsor: Perceive Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Which lens implant delivers sharper sight after cataract surgery?
Disease control OngoingThis trial compares two types of intraocular lenses implanted during cataract surgery: the Clareon PanOptix and the Tecnis Odyssey. About 266 adults with cataracts in both eyes will receive one lens type in each eye, and researchers will measure how well they see at various dista…
Sponsor: Nvision Laser Eye Centers • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Eye transplant showdown: which surgery saves sight best?
Disease control OngoingThis study compares two types of corneal transplant surgery (UT-DSAEK and DMEK) in 160 people with Fuchs dystrophy, a condition that clouds the cornea. It also tests whether a drug called rho-kinase inhibitor can reduce loss of important eye cells after surgery. The goal is to fi…
Phase 3 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Which lens implant method stays put better? a Head-to-Head test
Disease control OngoingThis study looks at whether the way a toric intraocular lens is implanted during cataract surgery affects how well it stays in place. Toric lenses correct astigmatism, but if they rotate after surgery, vision can blur. The trial compares two techniques: one using a gel-like subst…
Sponsor: Ain Shams University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control By invitation onlyThis early-stage trial is testing a new treatment called GPC2 CAR T cells for children with neuroblastoma or retinoblastoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize a…
Phase 1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a JAK inhibitor tame the immune attack in NMOSD?
Disease control OngoingThis early-phase trial tests whether baricitinib, an oral drug that blocks certain immune signals, can reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare autoimmune condition where the immune system attacks the optic nerves and spinal c…
Phase 1 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can an antioxidant slow vision loss? new trial tests NAC for retinitis pigmentosa
Disease control OngoingThis study is testing the long-term safety of a high-dose antioxidant called N-Acetylcysteine (NAC) in 30 adults with retinitis pigmentosa, an inherited eye disease that causes gradual vision loss and blindness. Participants take 1800 mg of NAC twice daily for two years, with reg…
Phase 1 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo shows promise for rare eye cancer
Disease control OngoingThis study tested two drug combinations in 42 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal was to see if adding a second drug (GSK2141795) to trametinib could better slow cancer growth. Participants were randomly assigned to receive either tram…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a One-Time gene therapy offer lasting protection for diabetic retinopathy?
Disease control By invitation onlyThis study is a long-term follow-up for people who previously received an injection of RGX-314, a gene therapy, for diabetic retinopathy (with or without diabetic macular edema). The purpose is to monitor the safety and effectiveness of the treatment over a total of five years af…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a One-Time gene therapy tame wet AMD for years?
Disease control By invitation onlyThis study follows people who previously received an experimental gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see how safe and effective the treatment remains over up to five years after the injection.…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New eye drug could cut wet AMD shots to just twice a year
Disease control OngoingThis study tests whether faricimab, an already-approved eye injection, can be given every 24 weeks (about twice a year) to people newly diagnosed with wet age-related macular degeneration (AMD). The trial involves 274 participants and will measure how well vision is maintained ov…
Phase 4 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy trial aims to restore night vision in rare eye disease
Disease control OngoingThis study tests a gene therapy called OCU400 for people with retinitis pigmentosa, an inherited eye disease that causes vision loss. The treatment is injected under the retina to help light-sensitive cells work better. The trial enrolled 140 people aged 3 and older and measures …
Phase 3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New eye injection could spare sight in melanoma patients
Disease control OngoingThis Phase 3 trial tests a new drug called belzupacap sarotalocan (AU-011) for people with small choroidal melanoma or suspicious spots in the eye. The drug is injected into the eye and activated by a laser to target cancer cells. The study compares it to a sham (fake) procedure …
Phase 3 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy trial aims to halt blindness in dry AMD
Disease control OngoingThis study tests a gene therapy called OCU410 for geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. About 60 adults aged 50 and older will receive a single injection of OCU410 into the eye. Researchers will monitor safety and check…
Phase 1/2 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Gene therapy slows vision loss in stargardt disease trial
Disease control OngoingThis study tests a new gene therapy called OCU410ST for people with Stargardt disease, an inherited eye condition that causes vision loss. Early results show the treatment slowed damage to the retina by nearly half and improved or stabilized eyesight in all treated patients. The …
Phase 2/3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Laser showdown: which glaucoma protocol wins?
Disease control OngoingThis study compares different ways of performing a laser treatment called selective laser trabeculoplasty (SLT) for people with open-angle glaucoma or high eye pressure. 400 participants will receive SLT using one of several protocols, and researchers will track how much their ey…
Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a donor corneal disc heal scarred eyes from herpes?
Disease control By invitation onlyThis trial tests whether implanting a thin disc of donor cornea tissue — called a stromal lenticule — can improve corneal transparency and vision in people with herpetic stromal keratitis, a herpes infection that scars the cornea. The lenticule contains stem cells and other livin…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a donated corneal lens fix farsightedness after cataract surgery?
Disease control OngoingThis trial tests whether implanting a fresh, donated corneal lenticule — a thin layer of corneal tissue — can safely correct residual farsightedness in people who already have an artificial lens implant after cataract surgery. The procedure uses a femtosecond laser to create a po…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a donated corneal lens correct hard-to-tract high hyperopia and astigmatism?
Disease control OngoingThis trial tests whether implanting a fresh corneal lenticule — a thin layer of donor cornea — can improve vision in people with high hyperopia (farsightedness) and high astigmatism. The lenticule is placed using a femtosecond laser, aiming to increase visual acuity and reduce as…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a lenticule implant clear cloudy corneas from viral infection?
Disease control OngoingThis trial tests a two-part approach for people with corneal scarring caused by adenoviral keratitis. Surgeons first remove the scarred tissue using a laser technique called SMILE, then implant a fresh, clear corneal lenticule of the same size into the pocket. Patients also recei…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a donor corneal lenticule patch up a thinning cornea?
Disease control OngoingThis case report tests whether implanting a fresh corneal lenticule from a myopic donor, along with autologous serum drops, can safely thicken the cornea and improve vision in a person with advanced keratoconus. The procedure uses a femtosecond laser to place the graft. The goal …
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a donor lens implant restore clarity to clouded corneas?
Disease control By invitation onlyThis trial investigates whether implanting a fresh corneal lenticule — a thin layer of donor cornea taken from myopic patients — can improve transparency and vision in people with macular corneal dystrophy, a condition that clouds the cornea. Using a femtosecond laser, surgeons r…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
A piece of your own cornea might patch a thinning one — a trial puts it to the test
Disease control By invitation onlyThis trial tests whether a corneal lenticule — a thin disc of tissue taken from a donor eye during a type of laser surgery — can be implanted into the cornea of people with progressive keratoconus, a condition where the cornea thins and bulges outward. The goal is to increase cor…
Sponsor: Dr. Faruk Semiz • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
A donated corneal lens may fix blurry vision after a cornea transplant
Disease control OngoingThis trial tests whether implanting a fresh, donated corneal lenticule into the eye can reshape the cornea and reduce irregular astigmatism in people who have already had a full cornea transplant. The goal is to improve visual acuity and stabilize the cornea's shape. Twenty-four …
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Laser touch-up may sharpen blurry vision after cataract surgery
Disease control By invitation onlyThis trial tests whether a laser procedure called Relex-Smile can correct leftover nearsightedness or farsightedness in people who had cataract surgery six months earlier. About 130 participants with blurry vision after receiving a trifocal lens implant will undergo the laser tre…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat eye cancer?
Disease control OngoingThis trial tests an experimental drug called DYP688 in people with metastatic uveal melanoma, a rare eye cancer that has spread, and other melanomas with specific genetic mutations. The study aims to find a safe dose and see whether the drug can shrink tumors. Participants receiv…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Alga supplement could boost sight in rare eye disease
Disease control By invitation onlyThis study tests whether a natural supplement from Dunaliella alga, rich in 9-cis beta-carotene, can improve vision in adults with retinitis pigmentosa. Forty-one participants will take the supplement or a placebo for 3 months, then switch after a 6-month break. Researchers will …
Phase 1/2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New glaucoma surgery under the microscope: 300 patients tracked for 2 years
Disease control OngoingThis study follows 300 adults with open-angle glaucoma who had a surgery called CycloPen™ to lower eye pressure. Researchers will check if the surgery safely reduces eye pressure by at least 20% and if patients need fewer eye drops over 24 months. The goal is to see how well this…
Sponsor: Iantrek, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New eye surgery could help glaucoma patients ditch drops
Disease control By invitation onlyThis study is watching 300 people with open-angle glaucoma who get a new type of eye surgery called bio-reinforced canaloplasty. The surgery aims to improve fluid drainage inside the eye to lower pressure. Participants will have regular eye check-ups for two years to see how well…
Sponsor: Iantrek, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can special contacts or atropine drops slow nearsightedness in kids?
Disease control OngoingThis trial tests three approaches to slow the progression of nearsightedness (myopia) in children aged 5 to 12: daily atropine eye drops, MiSight contact lenses, and NaturalVue multifocal contact lenses. Over two years, researchers will measure changes in eye length and prescript…
Phase 2 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New surgical tool aims to lower eye pressure in glaucoma patients
Disease control OngoingThis study follows 100 adults with primary open-angle glaucoma who had a goniotomy procedure using the C-Rex surgical instrument. The goal is to see how well the surgery lowers intraocular pressure and reduces the need for glaucoma medications over 12 months. Researchers will als…
Sponsor: Iantrek, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Own stem cells Gene-Hacked to fight rare hurler syndrome
Disease control OngoingThis study tests a one-time gene therapy for children with Hurler syndrome, a severe genetic disorder. Doctors take the child's own blood stem cells, add a working copy of the missing gene, and put them back. The goal is to help the body produce the enzyme it lacks, potentially s…
Phase 1/2 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could special glasses stop nearsightedness from getting worse?
Disease control By invitation onlyThis study tests whether special spectacle lenses called DIMS (defocus incorporated multiple segment) can slow the progression of nearsightedness (myopia) in university students aged 18 to 23. Participants wear either the DIMS lenses or standard single-vision glasses for comparis…
Sponsor: University of Bradford • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Eye-Opening study: amino acids may slow nearsightedness in young adults
Disease control OngoingThis study tests whether taking branched-chain amino acid (BCAA) supplements for six months can slow the progression of myopia (nearsightedness) in young adults aged 18 to 25. Participants either receive BCAA supplements plus standard glasses or a placebo plus glasses. The goal i…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New glasses could help Kids' eyesight stop getting worse
Disease control OngoingThis trial tests whether special spectacle lenses called Diffusion Optics Technology (DOT) lenses can slow the progression of nearsightedness (myopia) in Chinese children aged 6 to 13. Over 12 months, 195 children will wear either the DOT lenses or standard single-vision lenses. …
Sponsor: SightGlass Vision, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Micro-Coil stent aims to drain glaucoma pressure during cataract surgery
Disease control OngoingThis study tests a small, coiled stent designed to widen a natural drainage channel in the eye, helping fluid drain and lower pressure in people with open-angle glaucoma. Participants receive the stent in one eye at the same time as cataract surgery. The goal is to see if the ste…
Sponsor: Aquea Health, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a daily pill replace IV infusions for gaucher type 3?
Disease control OngoingThis phase 3 trial tests venglustat, a daily oral drug, against the standard IV treatment Cerezyme in 43 people with Gaucher disease type 3. Participants must have been on enzyme replacement therapy for at least 3 years. The goal is to see if venglustat can stabilize or improve n…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Eye implant could replace monthly shots for diabetes-related vision loss
Disease control OngoingThis study tests a small, refillable implant placed in the eye that delivers medication every 24 weeks, compared to standard monthly eye injections. It includes about 634 adults with diabetic macular edema, a condition that causes vision loss. The goal is to see if the implant wo…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could a pill replace infusions for gaucher brain symptoms?
Disease control OngoingThis phase 2 trial tests an oral drug called venglustat, given alongside the standard enzyme therapy Cerezyme, in adults with Gaucher disease type 3 (a rare genetic disorder affecting the body and brain). The study has four parts: first, it checks spinal fluid biomarkers to disti…
Phase 2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New eye injection aims to slow blindness in rare genetic disease
Disease control OngoingThis study tests an experimental drug called ultevursen for people with retinitis pigmentosa caused by a specific gene mutation (USH2A). The drug is injected into the eye and may help slow vision loss. The trial involves 81 participants, some of whom will receive a sham (fake) in…
Phase 2 • Sponsor: Laboratoires Thea • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Eye implant could replace daily drops for glaucoma
Disease control OngoingThis clinical trial tests an implant called PA5108 that is placed inside the eye to lower pressure in adults with open-angle glaucoma or ocular hypertension. The implant is compared to standard latanoprost eye drops. The study aims to find the right dose that is both safe and eff…
Phase 2 • Sponsor: PolyActiva Pty Ltd • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Contact lenses that could slow nearsightedness in kids
Disease control OngoingThis study tests whether MiSight 1 Day contact lenses can slow the progression of myopia (nearsightedness) in children aged 8 to 12. Participants wear either MiSight 1 Day or standard Proclear 1 day lenses for three years, then all switch to Proclear for one year to see if the ef…
Sponsor: CooperVision, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Contact lens safety check for kids with myopia
Disease control OngoingThis study looks at the safety of MiSight 1 Day contact lenses in children aged 8 to 12 with nearsightedness (myopia). Participants wear the lenses daily for three years, and researchers track eye infections and other problems. The goal is to confirm that these lenses are safe fo…
Sponsor: CooperVision, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to boost immune system against advanced cancers
Disease control OngoingThis early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…
Phase 1 • Sponsor: iOnctura • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could removing preservatives from glaucoma drops save Patients' eyes?
Disease control OngoingThis study compares two versions of a three-drug combination eye drop for glaucoma: one with preservatives and one without. Researchers want to see if the preservative-free version is gentler on the eye surface and leads to better treatment adherence. Participants will also use a…
Phase 4 • Sponsor: Tecnoquimicas • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
One surgery, two problems: new device takes on glaucoma and cataracts together
Disease control OngoingThis study tests a new device called the Helix Surgical System in people who have both primary open-angle glaucoma and cataracts. The device is used during cataract surgery to open up the eye's natural drainage channels, which may help lower eye pressure. The goal is to see if th…
Sponsor: Sight Sciences, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a home eye scanner replace frequent doctor visits for wet AMD?
Disease control OngoingThis Phase 3 trial tests whether people with wet age-related macular degeneration can use a home optical coherence tomography (OCT) device to guide when they need eye injections, instead of following a fixed schedule. 600 participants will either receive faricimab injections on a…
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Stem cell eye transplant aims to halt blindness from rare genetic disease
Disease control OngoingThis study tests whether transplanting lab-grown retinal cells (derived from human embryonic stem cells) into the back of the eye can safely slow or improve vision loss in people with retinitis pigmentosa, a genetic condition that causes gradual blindness. Participants must have …
Phase 1 • Sponsor: Qi Zhou • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a blood extract save sight? early trial tests PRP for rare eye diseases
Disease control OngoingThis pilot study tests whether injections of platelet-rich plasma (PRP) made from a patient's own blood can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants receive three injections over four months, and researchers …
Phase 1/2 • Sponsor: Rubens Camargo Siqueira • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New eye surgery device put to the test in 205 patients
Disease control OngoingThis study is testing a new device called Virtuoso for eye surgeries like cataract removal and vitrectomy. The goal is to make sure it is safe and works well. About 205 adults who need these surgeries will take part. The study will compare how often problems happen during surgery…
Sponsor: Beaver-Visitec International, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can your own blood help regrow thinning eyebrows?
Disease control OngoingThis study investigates whether injecting platelet-rich plasma (PRP) from a person's own blood can improve mild to moderate eyebrow thinning. Participants receive either PRP or saline injections into the eyebrows, and changes are tracked through photographs over nine months. The …
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental gene therapy aims to halt devastating brain disease in infants
Disease control PausedThis study tests a gene therapy called PBKR03 for babies with early infantile Krabbe disease, a severe genetic disorder that damages the brain and nerves. The treatment delivers a working copy of the GALC gene to the brain and body. Researchers will check safety and find the best…
Phase 1/2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
One-Time gene therapy aims to halt rare, fatal brain disease in children
Disease control OngoingThis study tests a single dose of PBGM01, a gene therapy delivered directly into the fluid around the brain and spinal cord, in children with GM1 gangliosidosis. The therapy uses a harmless virus to carry a working copy of the GLB1 gene, which is missing or faulty in these patien…
Phase 1/2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can an arthritis drug save sight? small trial tests adalimumab for rare eye diseases
Disease control OngoingThis pilot study tests whether adalimumab, an anti-inflammatory drug, can help preserve vision in people with retinitis pigmentosa or a related condition called EMAP. Thirty participants will receive three injections into the eye over four months. The main goal is to see if the t…
Phase 1/2 • Sponsor: Centro de Pesquisa Rubens Siqueira • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could donated tissue help heal stubborn wounds? new study investigates
Disease control OngoingThis early-stage study is testing whether a specially prepared membrane made from donated human tissue can help heal chronic wounds, like diabetic foot ulcers and eye surface injuries. The membrane is sterilized with different doses of radiation to find the best balance between s…
Phase 1 • Sponsor: Libyan Center for Biotechnology Research • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Eye-Directed chemotherapy aims to save sight in children with retinoblastoma
Disease control OngoingThis phase 2 trial tests whether giving chemotherapy directly into the eye (subconjunctival carboplatin) along with systemic topotecan can shrink advanced retinoblastoma tumors in children with disease in both eyes. The goal is to preserve the eye and vision, avoiding removal. Pa…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control PausedThis study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…
Phase 1/2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could special contact lenses slow worsening eyesight in young adults?
Disease control By invitation onlyThis study tests whether dual focus contact lenses (MiSight) can slow the progression of nearsightedness (myopia) in university students aged 18 to 21. Participants wear either the test lenses or standard single vision lenses for at least 10 hours a day. Researchers measure chang…
Sponsor: University of Bradford • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Laser eye surgery showdown: which fix for nearsightedness is better?
Disease control OngoingThis study compares two common laser eye surgeries—KLEx and FS-LASIK—for treating nearsightedness and astigmatism. Researchers will follow 80 adults aged 21 and older to see which procedure provides better vision without glasses and has fewer side effects. Both surgeries reshape …
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Gene therapy shot into both eyes aims to save sight in rare blindness
Disease control OngoingThis study tests a gene therapy called laruparetigene zovaparvovec (AGTC-501) in 10 males aged 12-50 with X-linked retinitis pigmentosa, a genetic condition that leads to vision loss. The therapy is injected into both eyes to deliver a working copy of the RPGR gene. The main goal…
Phase 2 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
CAR-T therapy targets autoimmune diseases, but trial never started
Disease control CancelledThis study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…
Phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
One-Time gene injection aims to halt rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e, a gene therapy that delivers a working copy of the CYP4V2 gene directly into the retina. It is for adults with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The trial will check wh…
Phase 1/2 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to tame Sjogren's syndrome in major trial
Disease control OngoingThis phase 3 study tests whether ianalumab, a biologic drug, can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 506 adults with a recent diagnosis (within 7.5 years) and positive anti-Ro/SSA antibodies are randomly assigned to receive ianalum…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple eye treatment stop the need for a corneal transplant?
Disease control OngoingThis registry collects long-term data from hundreds of people in Germany who have undergone corneal cross linking for keratoconus, a condition where the cornea thins and bulges, causing vision loss. The procedure uses riboflavin (vitamin B2) eye drops and UV light to stiffen the …
Sponsor: Suphi Taneri • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New contact lenses aim to slow nearsightedness in kids
Disease control OngoingThis study compares two types of contact lenses for slowing myopia (nearsightedness) in children aged 8 to 14. Over three years, researchers will measure changes in eye length and vision to see if the new lens works as well as the existing one. The goal is to help kids maintain b…
Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New glasses film may help Kids' eyesight stop getting worse
Disease control OngoingThis study tests special spectacle films designed to slow down myopia (nearsightedness) in children. About 210 kids aged 6 to 14 are taking part. The films use a new technology called S.T.O.P.® that creates changing visual cues, which may help control how fast the eye grows and p…
Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy injection aims to restore sight in rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e gene therapy for people with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The therapy delivers a working copy of the CYP4V2 gene directly to the retina. Researchers will measure wh…
Phase 3 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Antioxidant pill shows promise in slowing blindness
Disease control OngoingThis phase 3 trial tests whether an oral antioxidant called N-acetylcysteine (NAC) can slow the loss of vision in people with retinitis pigmentosa, an inherited eye disease that causes gradual blindness. About 485 adults aged 18 to 65 are taking NAC or a placebo for several years…
Phase 3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Glaucoma implant MINIject put to the test in everyday eye clinics
Disease control OngoingThis registry tracks 320 adults with open-angle glaucoma who receive the MINIject implant, a tiny device placed in the eye to help drain fluid and lower pressure. Researchers collect information on any unexpected complications and how surgeons rate the device's ease of use over t…
Sponsor: iSTAR Medical • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Glaucoma implant under the microscope: 5-Year safety watch begins
Disease control OngoingThis study follows 116 people with open-angle glaucoma who already have a MINIject implant in their eye. Researchers will track them for up to 5 years to see if any serious device-related problems occur. No new treatment is given—this is a safety check to see how well the implant…
Sponsor: iSTAR Medical • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a new eye drop boost laser results for glaucoma patients?
Disease control OngoingThis study tests whether Rhopressa eye drops can further lower eye pressure in people with glaucoma or high eye pressure who recently had laser surgery (SLT) in both eyes. About 70 adults will receive either Rhopressa or placebo drops daily for several weeks. The goal is to see i…
Phase 4 • Sponsor: East Coast Institute for Research • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
MS drug may shield eyes from damage, new study hopes to prove
Disease control By invitation onlyThis study looks at whether the drug ofatumumab can slow down thinning of the retina (the light-sensitive layer at the back of the eye) in people with relapsing-remitting multiple sclerosis (MS). Researchers will follow 75 adults with MS who are either starting or already taking …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells aim to tame autoimmune attacks
Disease control PausedThis early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…
Early phase 1 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can ear acupressure plus eye drops curb Kids' myopia?
Disease control By invitation onlyThis pilot study tests whether combining low-dose atropine eye drops (0.01% or 0.025%) with ear acupressure can safely slow myopia progression in 420 children aged 6-12. Participants are randomly assigned to one of six groups, including placebo, and are followed for 12 weeks. The…
Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Bionic eye implant aims to bring back sight in advanced macular degeneration
Disease control OngoingThis study tests a device called the PRIMA System, which includes an implant placed under the retina and a special visual processor worn by the patient. The goal is to help people with advanced dry age-related macular degeneration (geographic atrophy) regain some central vision. …
Sponsor: Science Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Gene therapy after stem cell transplant shows promise for rare brain disease
Disease control OngoingThis study tests a one-time gene therapy infusion (FBX-101) given after a standard stem cell transplant in 6 children with infantile Krabbe disease, a severe genetic disorder affecting the nervous system. The therapy uses a harmless virus to deliver a working copy of the GALC gen…
Phase 1/2 • Sponsor: Forge Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New glasses lens may slow kids' worsening eyesight
Disease control OngoingThis study tests a new type of eyeglass lens designed to slow down nearsightedness (myopia) in children. Fifty kids aged 6 to 15 will wear the special lenses for six months. Researchers will measure changes in the eye's thickness and length to see if the lens works and is safe.
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy shows promise against rare eye cancer
Disease control OngoingThis phase 2 trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink tumors in people with metastatic uveal melanoma, a rare and aggressive eye cancer. Participants receive chemotherapy to prepare their immune system, then an infu…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising drug may halt devastating NMOSD attacks faster
Disease control OngoingThis study tests whether eculizumab can help people having a sudden attack of NMOSD, a rare autoimmune disease that damages the nerves in the eyes and spine. The drug works by blocking part of the immune system to stop nerve injury. About 110 adults who test positive for a specif…
Phase 2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New eye implant aims to lower glaucoma pressure
Disease control By invitation onlyThis study is testing a device called XEN63, a small implant placed in the eye to help drain fluid and lower pressure in people with glaucoma. Researchers will follow 96 patients for 24 months to see if the implant safely reduces eye pressure and the need for daily eye drops. The…
Sponsor: Mario Stirpe • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug could cut repeat eye surgeries in diabetics
Disease control By invitation onlyThis study tests whether the drug farcimab (Vabysmo), given as an injection before and after eye surgery, can reduce bleeding complications in people with diabetes who have bleeding inside the eye. About 100 adults will receive either farcimab or a sham injection. The goal is to …
Phase 4 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental eye drug shows promise for rare Blindness-Causing disease
Disease control OngoingThis study tests an experimental drug called VP-001 for people with a rare genetic eye disease that causes vision loss. The drug is injected into the eye and aims to slow or stop further damage. Researchers will check safety and measure any changes in eyesight over about two year…
Phase 1/2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug pegtibatinase tested for rare metabolic disorder over two years
Disease control By invitation onlyThis study tests the long-term safety and effectiveness of pegtibatinase in people with classical homocystinuria (HCU), a rare genetic disorder that prevents the body from breaking down certain amino acids. About 100 participants who completed earlier studies will receive the dru…
Phase 3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Eye drops may halt worsening nearsightedness in adults
Disease control OngoingThis study tests whether eye pressure-lowering medication can slow the progression of severe nearsightedness (high myopia) in adults. Researchers will measure changes in eye length and vision over time. The trial includes 152 participants aged 18 to 65 with worsening high myopia …
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New eye injection shows promise for Diabetes-Related vision loss
Disease control OngoingThis study tests a new eye injection called IBI302 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. About 150 adults aged 18-80 with type 1 or 2 diabetes and swelling in the center of the retina will receive either IBI302 or an active c…
Phase 2 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis Phase 3 trial tests a single injection of Ixo-vec gene therapy in 311 people with wet age-related macular degeneration (AMD). The goal is to see if it can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up treatments. Participants…
Phase 3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
One-Patient trial hopes to slow rare eye and nerve disease
Disease control By invitation onlyThis early-phase trial tests an experimental drug called nL-FLVC-001 in a single person with posterior column ataxia with retinitis pigmentosa (PCARP), a rare genetic condition that causes vision loss and coordination problems. The drug is an antisense oligonucleotide injected in…
Early phase 1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New glasses film aims to stop kids' eyesight from getting worse
Disease control OngoingThis study tests whether a special film applied to glasses can slow the progression of nearsightedness (myopia) in children aged 6 to 14. The film uses A.R.R.E.S.T.® technology, which is designed to send specific light signals to the eye to control its growth. Over two years, res…
Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New eye drop targets Mite-Related eyelid inflammation in phase 2 trial
Disease control OngoingThis study tests a new eye drop (APT-001, containing spinosad 1.8%) for blepharitis, a condition causing red, irritated eyelids often linked to tiny mites. About 100 people with symptoms will receive either the active drop or a placebo. The goal is to see if the treatment clears …
Phase 2 • Sponsor: Aperta Biosciences, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New glasses could slow kids' worsening eyesight
Disease control OngoingThis study tests whether special glasses with P.A.U.S.E. technology can slow the progression of nearsightedness (myopia) in children. About 205 Vietnamese children aged 6-14 will wear either the special lenses or regular glasses for one year, then all will wear the special lenses…
Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Telescope eye implant study for AMD withdrawn before it began
Disease control CancelledThis study planned to test a small telescope implant inside the eye for people with severe vision loss from advanced age-related macular degeneration (AMD). The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the trial wa…
Sponsor: VisionCare, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
One-Time eye injection could slow blindness in retinitis pigmentosa
Disease control OngoingThis study tests a gene therapy called SPVN06 for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment is given as a single injection under the retina. The trial includes 33 adults with advanced disease and will check safety and whether it…
Phase 1/2 • Sponsor: SparingVision • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New eye drug takes on leading cause of blindness in the elderly
Disease control OngoingThis study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New eye drop shows promise for glaucoma control in chinese patients
Disease control OngoingThis study tests a new eye drop called DE-117B in 345 Chinese adults with open-angle glaucoma or high eye pressure. The goal is to see if it safely lowers eye pressure better than an existing drug. Participants use the drops once daily for at least 4 weeks, with long-term follow-…
Phase 3 • Sponsor: Santen Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Eye-Strengthening light therapy tested to halt blinding cornea disease
Disease control OngoingThis phase 3 trial tests a procedure called corneal collagen crosslinking for people with progressive keratoconus, a condition where the cornea thins and bulges, blurring vision. The treatment uses riboflavin (vitamin B2) drops and UV light to stiffen the cornea. The study aims t…
Phase 3 • Sponsor: Sahlgrenska University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Laser combo may cut eye injection burden for vein blockage patients
Disease control OngoingThis study looks at whether adding targeted laser treatment to the standard ranibizumab injections can help people with macular edema (swelling) from a central retinal vein occlusion need fewer injections over time. About 88 adults with this condition will receive either injectio…
Phase 3 • Sponsor: University of Giessen • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New lens aims to match top cataract implant in vision quality
Disease control OngoingThis study compares a new domestic trifocal lens (D615L) to the Zeiss AT LISA tri 839MP for people having cataract surgery. 90 adults with age-related cataracts will receive one of the two lenses and be followed for 6 months to measure vision at different distances. The goal is t…
Sponsor: Shanghai 10th People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New eye injection aims to stop vision loss in dry AMD patients
Disease control OngoingThis study tests whether monthly eye injections of ANX007 can prevent significant vision loss in people with dry age-related macular degeneration (AMD) that has progressed to geographic atrophy. About 659 participants will receive either the drug or a sham injection. The main goa…
Phase 3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New glasses could slow Kids' nearsightedness over 3 years
Disease control OngoingThis study tests special glasses with Diffusion Optics Technology to see if they can slow the progression of nearsightedness (myopia) in children. About 200 kids who completed a previous study will wear these glasses for up to 3 years. Researchers will measure changes in eye leng…
Sponsor: SightGlass Vision, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New glasses aim to stop kids' eyesight from getting worse
Disease control OngoingThis 3-year study tests whether a new type of spectacle lens can slow the progression of nearsightedness (myopia) in children aged 6 to 10. A total of 266 kids will wear either the novel lenses or standard lenses, and researchers will measure changes in eye length and prescriptio…
Sponsor: SightGlass Vision, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Liver-Directed chemo shows promise for eye cancer metastases
Disease control OngoingThis phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New eye drug trial aims for safer wet AMD treatment
Disease control OngoingThis early-stage trial tests an experimental drug called OCU-10-C-110, given as an eye injection, in 24 people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability at different doses. Researchers will monitor for side effects over ti…
Phase 1 • Sponsor: Ocugenix Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Gene therapy watch: RGX-111 safety tracked in MPS i patients
Disease control By invitation onlyThis study checks the long-term safety of RGX-111, a gene therapy for people with MPS I (a rare genetic disorder). It follows 21 participants who already received the therapy in an earlier trial. Researchers will monitor side effects and measure changes in thinking and behavior o…
Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New eye drop combo aims to soothe dry eyes fast
Disease control By invitation onlyThis study tests whether using two eye drops together—Vevye (cyclosporine) and Flarex (a steroid)—can safely improve symptoms in adults with moderate to severe dry eye disease. Sixty participants will use Vevye twice daily and Flarex four times daily for one month. The goal is to…
Phase 4 • Sponsor: Canyon City Eyecare • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for wet AMD: two novel drugs enter final testing phase
Disease control OngoingThis Phase 3 study tests two new drugs, tarcocimab tedromer and tabirafusp tedromer, against the standard treatment aflibercept for wet age-related macular degeneration (AMD). The trial involves 675 participants who have not been treated before. The goal is to see if the new drug…
Phase 3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Gene therapy could end frequent eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to help the eye produce its own medicine to stop leaky blood vessels, potentially replacing the need for repeated eye injecti…
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for kids with eye inflammation: baricitinib trial shows promise
Disease control OngoingThis study tests whether baricitinib, an oral drug, is safe and effective for children aged 2 to 18 with active uveitis (eye inflammation) linked to juvenile arthritis or a related condition. Participants had not responded well to standard treatments. The main goal is to reduce e…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New eye implant aims to ease glaucoma pressure
Disease control OngoingThis study tests a small implant placed inside the eye to help drain fluid and lower pressure in people with open-angle or narrow-angle glaucoma. It is for adults whose eye pressure is not well controlled with eye drops. The main goal is to see if the implant safely reduces press…
Sponsor: Ciliatech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a zapping headband save your sight?
Disease control OngoingThis study tests whether long-term, mild electrical stimulation using a home device can safely slow vision loss in people with open-angle glaucoma. About 45 adults with moderate vision damage will use the device regularly. The goal is to see if this approach can protect the optic…
Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Special lenses could slow worsening eyesight in kids
Disease control OngoingThis study tests a new type of spectacle lens (DG2) designed to slow down nearsightedness (myopia) in children whose vision is getting worse quickly. 118 children aged 4–13 will wear these lenses for 4 years. Researchers will measure changes in their eye prescription and eye leng…
Sponsor: The Hong Kong Polytechnic University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New syringe design tested for common eye disease treatment
Disease control OngoingThis study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…
Phase 3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New injection every 8 weeks shows promise for thyroid eye disease
Disease control OngoingThis study tests a drug called TOUR006 in 79 people with active thyroid eye disease, a condition that causes eye bulging and inflammation. Participants receive either a low dose, high dose, or placebo injection every 8 weeks. The main goal is to see if the drug can reduce eye bul…
Phase 2 • Sponsor: Tourmaline Bio, Inc., a Novartis Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New nomogram may sharpen vision in keratoconus patients
Disease control OngoingThis study tests whether a new surgical guide (the Alfonso nomogram) helps doctors place corneal ring implants more effectively in people with moderate keratoconus. Twenty-five adults aged 18–35 with progressive disease received the implant. Researchers will measure changes in vi…
Sponsor: Assiut University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can fewer eye injections work just as well? new trial tests flexible dosing for diabetic macular edema
Disease control OngoingThis study compares two ways of giving faricimab, a drug injected into the eye, to treat diabetic macular edema (DME). One group gets injections on a fixed monthly schedule, while the other uses a 'treat and extend' approach where the time between injections is gradually lengthen…
Phase 4 • Sponsor: McMaster University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New shot could tame Sjögren's symptoms in major trial
Disease control OngoingThis phase 3 trial tests whether efgartigimod, given as a shot under the skin, can reduce disease activity in adults with moderate-to-severe primary Sjögren's disease. About 631 participants will receive either the drug or a placebo for 48 weeks, with an option to continue treatm…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Gene therapy for wet AMD: 4-Year safety check begins
Disease control OngoingThis study checks the long-term safety of a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (AMD), a condition that can cause severe vision loss. Participants already received the gene therapy in an earlier study and will be monitored for up …
Phase 1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Gene therapy offers hope for rare Blindness-Causing eye disease
Disease control OngoingThis study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive one of two doses of the therapy or no treatment, and researchers measure changes in vision under low ligh…
Phase 2/3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New lens design aims to halt worsening eyesight in children
Disease control By invitation onlyThis study tests whether specially designed eyeglass lenses can slow the progression of myopia (nearsightedness) in children aged 6 to 14. Researchers will measure changes in eye length and prescription over time, while also checking for safety and comfort. The goal is to find a …
Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a Parkinson's drug protect eyes in diabetes?
Disease control By invitation onlyThis study tests whether levodopa, a drug used for Parkinson's, can slow blood vessel changes in the eyes of people with diabetes. Researchers will give the drug or a placebo to 244 patients with early diabetic retinopathy and measure retinal electrical activity and imaging over …
Early phase 1 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could vitamin B3 save sight in rare optic nerve disease?
Disease control OngoingThis study tests whether high-dose nicotinamide (vitamin B3) is safe and can help people with dominant optic atrophy, a rare genetic disease that slowly damages the optic nerve and causes vision loss. Researchers will give 25 adults 3 grams of nicotinamide daily and monitor for s…
Phase 2/3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill could tame Sjögren's syndrome
Disease control OngoingThis phase 3 trial tests deucravacitinib, an anti-inflammatory pill, in 774 adults with active Sjögren's syndrome. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug reduces disease activity and improves symptoms like dryness and fatigu…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New eye implant aims to lower pressure in glaucoma patients
Disease control OngoingThis early study tests a new drainage device for people with glaucoma, a condition where pressure builds up in the eye. The device is designed to self-adjust to help lower eye pressure. Ten participants will be followed to see if the device is safe and effective at reducing press…
Phase 1 • Sponsor: Rheon Medical SA • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for diabetic eyes: stronger dose may stop vision loss
Disease control OngoingThis study tests a higher dose (8mg) of aflibercept in 40 adults with proliferative diabetic retinopathy (PDR) who do not have swelling in the center of the retina. The goal is to see if this treatment can improve the severity of the disease and maintain vision over 96 weeks. Par…
Phase 4 • Sponsor: Edward Wood, MD • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New shot could tame Sjögren's Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can two existing drugs keep eye cancer from spreading?
Disease control OngoingThis phase 2 trial tests whether sunitinib or valproic acid can prevent uveal melanoma, a rare eye cancer, from spreading to other parts of the body in high-risk patients. 210 participants who have already had their primary tumor treated are randomly assigned to receive one of th…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Gene therapy trial for rare childhood disease halted Mid-Study
Disease control PausedThis study tests a gene therapy called RGX-111 for people with MPS I, a rare genetic disorder that damages the brain and body. The therapy delivers a working copy of the missing IDUA gene directly into the fluid around the brain. The trial aims to check if the treatment is safe a…
Phase 1/2 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New glasses lens could slow Kids' nearsightedness
Disease control OngoingThis study tests whether a special lens called Blue Star MAX-5 can slow the progression of nearsightedness (myopia) in children aged 8 to 11. Two hundred kids will wear either the new lens or standard glasses and be checked every six months for two years. The goal is to see if th…
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for rare eye disease: drug trial targets vision loss
Disease control OngoingThis study tests a drug called tinlarebant in 60 people with Stargardt disease, a genetic condition that causes vision loss. The goal is to see if the drug can slow damage to the retina and preserve eyesight. Participants take the drug or a placebo, and researchers measure change…
Phase 2/3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a daily shot help kids with rare bone diseases grow?
Disease control OngoingThis early study tests a daily injection of vosoritide (Voxzogo) in 6 children aged 5 to 10 with MPS IVA or VI, rare conditions that cause growth problems. The main goal is to see if the drug is safe and tolerable over 96 weeks. Researchers will also look at changes in height and…
Phase 1/2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
One-Time gene injection aims to restore sight in rare eye disease
Disease control OngoingThis phase 3 trial tests a gene therapy called LX101 in 30 people with inherited retinal dystrophy caused by RPE65 mutations. Participants receive a single injection of LX101 into the eye, while a control group gets no treatment. The study measures changes in functional vision an…
Phase 3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental gene therapy aims to restore sight in rare eye disease
Disease control OngoingThis early study tests a gene therapy called LX101 in 9 people with a rare inherited eye disease caused by RPE65 gene mutations. The therapy delivers a working copy of the gene into the retina via a single injection. The main goals are to check safety and see if it can improve vi…
Phase 1 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One-and-Done gene shot could spare wet AMD patients from monthly eye needles
Disease control OngoingThis phase 2 trial tests a gene therapy called LX102 for wet age-related macular degeneration (nAMD), a leading cause of vision loss. The therapy is injected under the retina and aims to produce a protein that blocks abnormal blood vessel growth, potentially reducing the need for…
Phase 2 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Desperate hope: gene therapy tested in one patient with rare blindness
Disease control Expanded access (ended)This expanded access program gave a single patient with Leber Hereditary Optic Neuropathy (a genetic cause of vision loss) an experimental gene therapy called GS010. The treatment was injected into both eyes to test safety. Only one person was involved, so the results are very li…
Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Glasses that 'Talk' to Gene-Edited eyes: a new hope for blindness?
Disease control OngoingThis early-stage trial tests a combination treatment for retinitis pigmentosa, a genetic disease that causes blindness. Ten adults receive a single injection of GS030 gene therapy into one eye, then use special glasses that send light signals to the treated retina. The main goal …
Phase 1/2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis study tests a gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment is given as one or two injections into the eye and aims to produce proteins that block abnormal blood vessel growth, potentially replacing …
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a stem cell transplant stop the immune system from attacking the brain?
Disease control OngoingThis phase 2 trial tests whether high-dose chemotherapy followed by a stem cell transplant can stop the immune system from attacking the nervous system in people with autoimmune neurologic diseases like multiple sclerosis and stiff person syndrome. The treatment aims to weaken th…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Gene therapy injection aims to restore sight in rare eye diseases
Disease control OngoingThis early-phase trial tests a single injection of a gene therapy called RTx-015 in 10 adults with retinitis pigmentosa or choroideremia, two inherited conditions that cause vision loss. The therapy delivers a gene that makes retinal cells produce a light-sensitive protein, poten…
Phase 1 • Sponsor: Ray Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New glasses aim to halt adult nearsightedness
Disease control OngoingThis study tests whether Essilor Stellest spectacle lenses can slow the progression of nearsightedness (myopia) in adults aged 18 to 40. Each participant wears a Stellest lens in one eye and a standard lens in the other, allowing direct comparison. The trial measures changes in e…
Sponsor: University of Ulster • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a lower dose of avastin save sight in preemies?
Disease control OngoingThis study tests whether lower doses of the drug bevacizumab (Avastin) can effectively treat a severe form of retinopathy of prematurity (ROP) in premature infants. The trial includes 77 babies with type 1 ROP in zone I, the most dangerous type. Each infant receives a single inje…
Phase 2 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
First gene therapy trial launches for rare childhood disease MLIV
Disease control By invitation onlyThis early-stage trial tests a gene therapy called AAV9.hMCOLN1co in one child with Mucolipidosis Type IV (MLIV), a rare genetic disorder. The therapy is given as a single injection into the spinal fluid. The main goal is to check safety, but researchers will also look for any si…
Phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Common heart drug may shield eyes of type 1 diabetes patients
Disease control OngoingThis study tests whether fenofibrate, a drug typically used to lower blood fats, can slow the worsening of diabetic retinopathy (eye damage) in adults with type 1 diabetes. Over 400 participants take either fenofibrate or a placebo daily for three years. The goal is to see if the…
Phase 3 • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Gene therapy for macular degeneration: is it safe years later?
Disease control OngoingThis study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it remains safe over time. Researchers track side effects and vision changes. The goal is to understand long-term risks, not to test if the treatment w…
Phase 1 • Sponsor: Oxford BioMedica • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill shows promise in Hard-to-Treat eye cancer
Disease control OngoingThis phase 2 trial tests a new drug called roginolisib against standard treatments in 85 adults with advanced uveal melanoma, a rare eye cancer. The study aims to see if roginolisib helps people live longer and improves their quality of life. Participants are randomly assigned to…
Phase 2 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill could tame debilitating eye inflammation, major trial underway
Disease control OngoingThis study tests an oral medication called brepocitinib in adults with active uveitis, a condition causing inflammation inside the eye. The goal is to see if the drug can prevent the disease from worsening and help maintain vision. About 371 participants will receive either the d…
Phase 3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for kids with eye cancer: extra chemo may stop spread
Disease control OngoingThis study looks at whether giving chemotherapy (and sometimes radiation) after removing the eye can prevent retinoblastoma from coming back in children. About 195 children with advanced retinoblastoma in one eye took part. The goal is to see if this extra treatment reduces the c…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a pill save your sight? new trial targets blinding eye disease
Disease control OngoingThis Phase 3 trial tests whether a daily pill called tinlarebant can slow the growth of geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 429 adults with the condition will receive either the drug or a placebo for up to 2 year…
Phase 3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Gene therapy could replace risky transplants for kids with hurler syndrome
Disease control OngoingThis Phase 3 trial tests a new gene therapy called OTL-203 against the standard stem cell transplant for children with Hurler syndrome, a rare genetic disorder. The therapy uses the child's own blood stem cells, modified to produce the missing enzyme, aiming to improve survival a…
Phase 3 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for rare autoimmune disease: eculizumab trial targets relapses
Disease control OngoingThis study tests a drug called eculizumab in Chinese adults with a rare autoimmune disease called NMOSD, which attacks the nerves in the eyes and spinal cord. The goal is to see if the drug can reduce the number of relapses (flare-ups) and slow disability. Participants must have …
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Exercise as medicine: HIIT may slow glaucoma damage
Disease control OngoingThis study tests whether high-intensity interval training (HIIT) can improve eye health and slow disease progression in people with glaucoma. 168 adults aged 40-75 with open-angle glaucoma will be randomly assigned to either a supervised HIIT program or standard care with lifesty…
Sponsor: Henner Hanssen • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill could fight diabetic eye swelling
Disease control OngoingThis Phase 2 trial tests whether the oral drug tonabersat can reduce retinal swelling in people with diabetic macular edema who still have good vision. About 128 adults with type 1 or 2 diabetes will take either tonabersat or a placebo daily for several months. The main goal is t…
Phase 2 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Dry eye drug combo safety trial pulled before it started
Disease control CancelledThis study was designed to check the long-term safety of a new eye drop that combines two active ingredients (lifitegrast and perfluorohexyloctane) for people with dry eye disease. It was a follow-up for people who had already completed an earlier study. However, the trial was wi…
Phase 3 • Sponsor: Bausch & Lomb Incorporated • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could wet AMD patients get fewer eye shots? new study tests early treatment breaks
Disease control OngoingThis study compares two drugs, aflibercept and brolucizumab, for wet age-related macular degeneration (AMD). Instead of the usual three monthly loading doses, it tests starting with longer intervals between injections right away. The goal is to see if this approach works just as …
Sponsor: Berner Augenklinik • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could peeling an extra layer during eye surgery prevent repeat detachment?
Disease control OngoingThis study compares two types of surgery for people with a detached retina. One group gets standard repair surgery, the other gets an extra step where a thin membrane is peeled away. Researchers want to see if this extra step lowers the chance of re-detachment and improves vision…
Sponsor: Berner Augenklinik • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New chemo cocktails aim to save eyes in kids with retinoblastoma
Disease control OngoingThis phase 2 trial tests different chemotherapy regimens in 133 children with retinoblastoma, a rare eye cancer. The goal is to shrink tumors and avoid removing the eye or using radiation. Treatments include intravenous and intra-arterial chemotherapy, sometimes combined with las…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Gene therapy boost for krabbe patients after transplant
Disease control OngoingThis early-phase trial tests a single infusion of a gene therapy called FBX-101 in 9 people with Krabbe disease who have already received a stem cell transplant. The therapy uses a harmless virus to deliver a working copy of the GALC gene, aiming to improve motor function and saf…
Phase 1/2 • Sponsor: Forge Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New study tracks immune effects of NMOSD drug over years
Disease control OngoingThis study looks at the long-term safety of inebilizumab (UPLIZNA) in people with neuromyelitis optica spectrum disorder (NMOSD). Researchers will measure immune markers like immunoglobulins and B-cells in 32 participants during treatment and after stopping. The goal is to unders…
Phase 4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Avastin vs eylea: which eye drug needs fewer shots?
Disease control OngoingThis study compares two drugs, Avastin and Eylea, given as eye injections for wet age-related macular degeneration (AMD). The main goal is to see which drug requires fewer injections over two years while still controlling the disease. Researchers will also check vision, eye thick…
Phase 2 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Gene therapy for gaucher disease: 5-year safety check begins
Disease control OngoingThis study follows 75 people with Gaucher disease type 1 who previously received FLT201 gene therapy. Researchers will monitor them for 5 years to see if the treatment remains safe and if its effects last. The goal is to understand whether a single dose can provide long-term dise…
Phase 1/2 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can ritalin Jump-Start the brain after a coma?
Disease control OngoingThis early-stage trial tests whether a stimulant drug (methylphenidate, also known as Ritalin) given through an IV can safely help people with severe brain injuries regain consciousness. Ten adults in a coma or minimally conscious state will receive increasing doses to check for …
Phase 1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Gene therapy for rare brain diseases: 5-Year safety check begins
Disease control OngoingThis study follows 7 people who previously received a gene therapy called AXO-AAV-GM2 for Tay-Sachs or Sandhoff disease — rare, fatal genetic disorders that destroy nerve cells. Researchers will track them for up to 5 years to see if the treatment remains safe and whether it help…
Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can repeat laser eye treatment keep glaucoma in check?
Disease control By invitation onlyThis study looks at the best way to repeat a laser treatment called SLT for people with open-angle glaucoma or high eye pressure. Researchers will compare different treatment methods in 400 participants who were already in an earlier SLT trial. The goal is to see how well repeat …
Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Laser showdown: where to zap the iris for better glaucoma control?
Disease control OngoingThis study tests two different spots (temporal vs inferior) for a YAG laser iridotomy in people with angle-closure glaucoma. Each patient gets one spot in each eye, and doctors track pressure, symptoms, and complications over six months. The goal is to find which location is safe…
Sponsor: Isfahan University of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New contact lens trial aims to stop worsening eyesight in children
Disease control OngoingThis study tests whether NaturalVue multifocal contact lenses can slow the progression of myopia (nearsightedness) in children aged 7 to 12. Over three years, 144 kids will wear either standard single-vision lenses or the multifocal lenses. Researchers will measure changes in the…
Sponsor: Visioneering Technologies, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo therapy aims to shrink eye tumors before radiation
Disease control By invitation onlyThis early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injectio…
Phase 1/2 • Sponsor: Hospital das Clínicas de Ribeirão Preto • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC
-
Promising NMOSD attack treatment trial pulled before it began
Disease control CancelledThis study aimed to test the drug eculizumab for people having an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition where the immune system attacks the central nervous system. The trial planned to give four weekly doses of eculizumab alongside standard s…
Phase 2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
Tiny eye implant could free glaucoma patients from daily drops
Disease control OngoingThis trial tests a small implant called MINIject that is placed inside the eye to help drain fluid and lower pressure in people with open-angle glaucoma. About 975 adults who have already had cataract surgery are taking part. The goal is to see if the implant safely reduces eye p…
Sponsor: iSTAR Medical • Aim: Disease control
Last updated Jun 26, 2026 16:47 UTC
-
New combo treatment aims to stop Kids' nearsightedness from getting worse
Disease control OngoingThis study tests whether combining low-dose atropine eye drops with special glasses (DIMS lenses) can slow the worsening of nearsightedness in children better than atropine alone. About 111 kids aged 4–16 with progressing myopia will be randomly assigned to one of two groups. The…
Phase 4 • Sponsor: Hospital San Carlos, Madrid • Aim: Disease control
Last updated Jun 26, 2026 15:44 UTC
-
New combo attack on eye cancer that spreads to the liver
Disease control OngoingThis study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus a chemotherapy drug (melphalan) given directly to the liver through a special procedure. It includes 83 adults with advanced uveal melanoma that has spread mainly to the liver. The goal is t…
Phase 1/2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Could a single lens implant replace daily eye drops for glaucoma?
Disease control OngoingThis study follows 23 people who received a special lens implant that slowly releases a glaucoma drug (bimatoprost) during cataract surgery. Researchers want to see if it keeps eye pressure low and vision clear for up to 7 years. The goal is to learn whether this combination devi…
Sponsor: SpyGlass Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:48 UTC
-
Could light and sound replace the air puff eye test?
Diagnosis OngoingThis trial evaluates a new device called the Photobionic IOP Tonometer (PIB) that measures eye pressure without touching the eye or using an air puff. It uses a low-power infrared light and a gentle sound to detect tiny movements on the eye's surface, which a computer analyzes to…
Sponsor: EyeCBetter Corporation • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
Your phone could soon spot blind spots
Diagnosis OngoingThis study is testing a smartphone app called eyeFusion that measures how fast your eye can detect flickering lights. The goal is to see if the app can help doctors quickly find blind spots (scotomas) in people with eye disorders. About 500 people, including healthy volunteers an…
Sponsor: Randy Kardon • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Smart contact lenses could revolutionize glaucoma monitoring
Diagnosis By invitation onlyThis study tests smart soft contact lenses that measure eye pressure continuously for 24 hours in people with glaucoma and healthy adults. Researchers will check how accurate and comfortable the lenses are compared to standard eye pressure tests. The goal is to improve glaucoma c…
Sponsor: Indiana University • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Seeing inside the eye during surgery: a new imaging tool could sharpen lens disease care
Diagnosis OngoingThis study looks at whether a special imaging technique called intraoperative optical coherence tomography (iOCT) can help doctors better diagnose and treat lens diseases like cataracts and lens dislocation. Researchers will review data from 1,200 patients who had lens surgery to…
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
New imaging tools put to the test for measuring dry eye treatment effects
Diagnosis OngoingThis study tests whether two specialized eye imaging devices—the LipiView II and Keratograph 5M—can detect changes in tear film stability after using Miebo eye drops in people with dry eye. Twenty adults with normal tear film will have their eyes measured before and at several ti…
Phase 4 • Sponsor: The Eye Care Institute • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
New york program offers extra screening for 100,000 newborns
Diagnosis By invitation onlyScreenPlus is a large pilot program that offers families the option to have their newborn screened for a panel of rare genetic disorders, in addition to standard newborn screening. The study aims to screen 100,000 infants born at eight hospitals in New York. Researchers will eval…
Sponsor: Albert Einstein College of Medicine • Aim: Diagnosis
Last updated Jul 30, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI eye check could save your sight: new trial tests smart screening for diabetes patients
Diagnosis By invitation onlyThis study tests whether using artificial intelligence (AI) to screen for diabetic eye disease during regular primary care visits helps more people get timely eye exams and follow-up care. About 1,700 adults with diabetes who haven't had an eye exam in the past year will take par…
Sponsor: University of Wisconsin, Madison • Aim: Diagnosis
Last updated Jun 27, 2026 12:26 UTC
-
New app could spot eye disease from your couch
Diagnosis By invitation onlyThis study is testing a smartphone app called NEDS EyeCTester to see if it can help detect active eye disease early in people with conditions like optic nerve or macular disease. About 100 participants will use the app at home, and researchers will compare the results to standard…
Sponsor: Neuro-Eye Diagnostic Systems, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Brain scan breakthrough could save babies from rare disease
Diagnosis OngoingThis study looks at whether a special brain scan called diffusion tensor imaging (DTI) can help doctors find Krabbe disease in newborns and decide who needs urgent treatment. About 100 babies with a positive newborn screen or family history of Krabbe disease will be scanned and f…
Sponsor: University of Pittsburgh • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
New eye test could replace painful scrape for infection diagnosis
Diagnosis CancelledThis study aimed to see if a soft membrane placed on the eye could diagnose microbial keratitis (a serious eye infection) better and more comfortably than the standard scrape test. Researchers planned to compare the two methods in adults with new corneal infections. However, the …
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
Revolutionary eye camera could catch blindness early
Diagnosis OngoingThis study tests a new, ultra-high-resolution eye scanner that combines two imaging techniques to see the retina in 3D. Researchers will scan 10 healthy adults and 40 people with early or intermediate age-related macular degeneration (AMD). The goal is to improve early detection …
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
AI eye exam could spot diabetes blindness before it starts
Diagnosis By invitation onlyThis study is testing whether an artificial intelligence (AI) program can spot early signs of diabetic retinopathy—a condition that can lead to blindness—in people with prediabetes and diabetes. Researchers will take pictures of the retina and use the AI to analyze them. The goal…
Sponsor: University Hospital Tuebingen • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
Eye-Tracking tech could spot macular degeneration faster
Diagnosis OngoingThis study tests a device called AVIGA that tracks eye movements to detect vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the device's results with standard eye exams to see if it can reliably spot disease activity. The goal is…
Sponsor: Tan Tock Seng Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
New ultrasound technique could spot eye tumors without a biopsy
Diagnosis OngoingThis study tests a special ultrasound technique called Superb Microvascular Imaging (SMI) to see blood flow inside eye tumors. The goal is to help doctors tell benign from malignant tumors more accurately, especially when standard tests are unclear. Twenty-two adults with untreat…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
AI could spot diabetic eye disease in minutes
Diagnosis OngoingThis study tests whether using artificial intelligence (AI) to screen for diabetic retinopathy is faster and more accessible than the usual method with an eye doctor. About 548 adults with diabetes will be randomly assigned to either standard screening or AI-based screening using…
Sponsor: Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
AI eye test: could a computer replace your eye doctor?
Diagnosis By invitation onlyThis study compares a new AI system, called AEYE, against a human eye doctor in diagnosing keratoconus and deciding who is eligible for laser vision correction. The AI analyzes patient history, eye scans, and other data to make its recommendations. Researchers will check if the A…
Sponsor: Hazem Yassin Clinics • Aim: Diagnosis
Last updated Jun 26, 2026 17:00 UTC
-
Eye drops may shield the cornea after cataract surgery
Prevention By invitation onlyResearchers are testing whether netarsudil eye drops can protect the cornea in people with Fuchs endothelial corneal dystrophy and glaucoma who have cataract surgery. The study enrolls 50 adults aged 40 to 90. Participants use either netarsudil or a placebo drop daily for four we…
Sponsor: University Hospital Dubrava • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
A simple fix for myopia could change education for millions
Prevention OngoingThis trial tests whether giving free glasses to short-sighted middle school children in rural China helps more of them continue to academic high school. Researchers will randomly assign 111 schools to either provide glasses with teacher support or just give prescriptions. The mai…
Sponsor: Queen's University, Belfast • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Can a daily vitamin and sunshine curb Kids' nearsightedness?
Prevention CancelledThis study tests whether taking vitamin B2 (riboflavin) daily and spending time outdoors in sunlight can slow the progression of myopia (nearsightedness) in children aged 6 to 12. Participants will be randomly assigned to receive different doses of riboflavin or a placebo, and al…
Phase 2 • Sponsor: University of Missouri-Columbia • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Can a pair of glasses slash motorcycle crashes?
Prevention OngoingThis trial tests whether providing free corrective glasses to young motorcycle drivers with myopia (nearsightedness) can reduce the number of crashes and near-misses. Participants are university students in Ho Chi Minh City who drive regularly and have uncorrected or under-correc…
Sponsor: Queen's University, Belfast • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Glowing light could spot oral cancer before it starts
Prevention By invitation onlyThis study investigates whether a painless fluorescent light exam can help find early warning signs of oral cancer in adults. Participants complete a health questionnaire and receive a standard oral exam plus a fluorescence scan. The goal is to see if this simple, non-invasive to…
Sponsor: Medical University of Warsaw • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Cheap pill could save millions from blindness, major trial launches
Prevention OngoingThis study tests whether fenofibrate, a drug already used for high cholesterol, can prevent diabetic retinopathy from worsening in people with mild to moderate disease. About 560 adults with diabetes will take either fenofibrate or a placebo for up to 6 years. The goal is to see …
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Prevention
Last updated Jul 01, 2026 00:00 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Eye surgery trial to prevent blindness in stickler syndrome pulled before start
Prevention CancelledThis study aimed to see if a surgical procedure called scleral buckling could prevent retinal detachment in people with Stickler syndrome, a genetic condition that raises the risk of vision loss. The plan was to treat one eye in patients aged 5 to 35 who had already lost vision i…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Dairy workers test special shoes to stop dangerous slips
Prevention OngoingThis study tests whether special slip-resistant shoes can help dairy workers avoid slipping on wet, slippery floors. About 22 full-time employees at a Danish dairy will wear different shoes and rate how slippery they feel each day. The goal is to find footwear that reduces fall r…
Sponsor: Aalborg University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
Red light therapy shows promise for Kids' eyesight
Prevention OngoingThis study looks at whether using a special red light device twice a day can help prevent or control nearsightedness (myopia) in children aged 5 to 16. Researchers are following 3,000 kids who have used the therapy for at least a year, some for up to three years or more. The goal…
Sponsor: Ruihua Wei • Aim: Prevention
Last updated Jun 26, 2026 14:54 UTC
-
Could a liver drug help people see color? tiny trial launched
Symptom relief PausedThis early-phase trial tests whether an FDA-approved drug called glycerol phenylbutyrate (PBA) can improve vision in people with a rare form of color blindness caused by mutations in the ATF6 gene. Only 2 participants are enrolled, and they will take PBA three times daily while t…
Early phase 1 • Sponsor: Columbia University • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Eye drops take aim at dry eye: phase 2 trial puts TJO-087 to the test
Symptom relief OngoingResearchers are testing an experimental eye drop called TJO-087 in adults with dry eye syndrome. The trial enrolls about 90 people who have dry eye symptoms and signs of corneal damage. Participants receive either TJO-087 or a placebo drop for 3 months. The main measure is whethe…
Phase 2 • Sponsor: Taejoon Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Spinal zaps and exercise may boost walking after injury
Symptom relief OngoingThis study tests whether combining motor skill training with a non-invasive spinal stimulation can improve walking, balance, and strength while reducing muscle spasticity in people with incomplete spinal cord injury. Twenty-eight participants will do a series of standing exercise…
Sponsor: Shepherd Center, Atlanta GA • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
New hope for kids with rare liver disease: long-term drug study launched
Symptom relief OngoingThis study looks at the long-term safety and effectiveness of odevixibat in 70 people with Alagille syndrome, a rare genetic condition that affects the liver and other organs. The drug aims to reduce severe itching and improve bile flow. Participants who completed a prior 24-week…
Phase 3 • Sponsor: Albireo, an Ipsen Company • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
New study checks if popular eye drops really soothe dry eyes
Symptom relief OngoingThis study is testing two versions of Tears Naturale lubricating eye drops—one with preservatives and one without—in 120 people with mild to moderate dry eye disease. Participants will stop using their usual artificial tears and use only the study drops for the duration of the tr…
Sponsor: Alcon Research • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
Free glasses may help seniors bank from home
Symptom relief OngoingThis study gives free reading glasses and basic smartphone training to older adults in Bangladesh who receive government benefits. The goal is to see if better vision helps them use mobile banking more often and independently. About 571 people aged 48 to 70 with presbyopia (age-r…
Sponsor: Queen's University, Belfast • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New lens tech aims to sharpen sight after cataracts
Symptom relief OngoingThis study tests new versions of Clareon Vivity Pro intraocular lenses (IOLs) to see if they improve vision better than current lenses. About 231 adults with cataracts in both eyes will receive one new lens and one current lens to compare results. The main goal is to measure how …
Sponsor: Alcon Research • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Pedal to preserve sight: study tests if exercise slows glaucoma damage
Symptom relief CancelledThis study looks at whether a 12-week home exercise program (cycling and resistance training) can improve vision and quality of life in people with glaucoma. Researchers will measure changes in visual field sensitivity, eye blood flow, and oxygen use. The goal is to see if exerci…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Laser touch-up after cataract surgery: can Relex-Smile fix leftover nearsightedness?
Symptom relief By invitation onlyThis trial tests whether Relex-Smile laser surgery can safely and effectively correct residual nearsightedness in people who still have blurry distance vision six months after cataract surgery. Participants will undergo the laser procedure and have their vision and refraction mea…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
A tiny corneal pocket may restore Close-Up vision — no glasses needed
Symptom relief By invitation onlyThis trial tests whether creating a small pocket inside the cornea using the SMILE module can improve near vision in people with presbyopia who want to avoid glasses. The procedure aims to increase the eye's ability to focus on close objects. Researchers are measuring how much ne…
Sponsor: Eye Hospital Pristina Kosovo • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Could a daily supplement soothe dry eyes?
Symptom relief By invitation onlyThis study tests whether an oral supplement that targets gut bacteria can improve dry eye symptoms in adults with moderate evaporative dry eye disease. Over 8 weeks, 130 participants will take either the supplement or a placebo. The main goal is to see if symptoms, measured by a …
Sponsor: Varol TUNALI • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Chin surgery showdown: can a Mini-Wing reshape both face and airway?
Symptom relief OngoingThis study compares two types of chin surgery—Box genioplasty and Mini-Wing genioplasty—in adults with a receding lower jaw (skeletal Class II deformity) who are also having jaw realignment surgery. The goal is to see which technique better improves the upper airway size and the …
Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Could your own blood cure dry eye? plasma drops put to the test
Symptom relief CancelledThis study tests whether eye drops made from a patient's own platelet-rich plasma can improve dry eye symptoms. Participants with dry eye syndrome will receive either platelet-rich plasma drops or plasma drops without platelets. The trial measures changes in vision, tear film qua…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New device aims to help NMOSD patients walk better
Symptom relief By invitation onlyThis study tests a device called MR-C-014 that uses sound to help people with neuromyelitis optica spectrum disorder (NMOSD) who have trouble walking. Thirty adults will use the device for 30 minutes, three times a week for 8 weeks. The main goals are to see if people find it acc…
Sponsor: MedRhythms, Inc. • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Talking it out: therapy group aims to ease parents' stress in rare blindness condition
Symptom relief OngoingThis study tests whether group psychotherapy can help parents of children with Leber congenital amaurosis (LCA) feel better emotionally and handle stress. Forty parents will take part, with half joining therapy groups and the other half serving as a comparison. Researchers will m…
Sponsor: Instituto de Genética Ocular • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Finger in mouth could cure dry eyes? small study tests odd technique
Symptom relief OngoingThis pilot study tests whether a specific hands-on technique inside the mouth can increase tear production in healthy adults aged 18-45. Thirty volunteers will have their tears measured before and after the procedure, with follow-up visits at 2 days and 1 week. The goal is to see…
Sponsor: Edward Via Virginia College of Osteopathic Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Nerve-Zapping gadget could tame MS symptoms at home
Symptom relief OngoingThis study tests if a gentle, non-invasive nerve stimulation device can help manage symptoms of multiple sclerosis (MS), like fatigue and pain. Thirty women with MS will use the device at home for a few weeks. The goal is to see if it's practical and if it reduces symptom burden,…
Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New cataract lens aims to sharpen vision at Arm's length
Symptom relief By invitation onlyThis study looks at how well a new type of lens, called Clareon TruPlus, helps people see clearly at intermediate distances (like a computer screen) after cataract surgery. About 50 adults with cataracts in both eyes will get this lens and be tested 12 weeks after surgery. The go…
Sponsor: Colvard Kandavel Eye Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Saffron study for dry eye pulled before it began
Symptom relief CancelledThis study aimed to see if a saffron-based supplement called AffronEye® could improve dry eye symptoms in university staff and students. It planned to compare the supplement to a placebo over 84 days using eye tests and symptom questionnaires. However, the study was withdrawn bef…
Sponsor: University of Alicante • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Sound-Guided gaze: new device aims to sharpen eye imaging for the visually impaired
Symptom relief By invitation onlyThis study tests a device that uses real-time sound feedback to help people with vision loss fix their gaze on a target. Participants hear sounds that guide their eyes back to center when they drift. The goal is to improve the quality of eye imaging by reducing blur from eye move…
Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Could stem cell eye drops finally soothe stubborn dry eyes?
Symptom relief OngoingThis early-phase trial tests whether eye drops made from mesenchymal stem cells can safely relieve symptoms in 10 women aged 40-60 with dry eye disease that didn't improve with artificial tears. Participants use the drops twice daily for two weeks and are followed for three month…
Early phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
New gel could make eye injections Pain-Free
Symptom relief By invitation onlyThis study compares a new numbing gel (chloroprocaine HCl 3%) to standard eye drops plus a shot for pain relief during eye injections. About 236 adults with conditions like diabetic macular edema or age-related macular degeneration will take part. The goal is to see if the gel wo…
Phase 4 • Sponsor: Harrow Inc • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
New eye gel could ease rosacea symptoms
Symptom relief By invitation onlyThis Phase 2 trial tests a gel called lotilaner for people with moderate to severe ocular rosacea, a condition causing red, irritated eyes. About 155 adults will receive either the gel or a placebo to see if it is safe and helps symptoms. The study is currently enrolling by invit…
Phase 2 • Sponsor: Tarsus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Diabetes cataract study pulled before starting
Symptom relief CancelledThis study was designed to compare a tiny steroid insert (Dextenza) placed in the tear duct against standard steroid eye drops (prednisolone) after cataract surgery in people with diabetes. The goal was to see which better controls eye inflammation and swelling. However, the stud…
Phase 4 • Sponsor: Baylor Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New laser surgery aims to sharpen vision for high astigmatism
Symptom relief OngoingThis study looks at how well SMILE PRO laser surgery corrects high astigmatism in people with nearsightedness. 113 patients aged 18 to 40 will have the procedure and be followed for a year to check vision sharpness, stability, and safety. The goal is to see if this advanced laser…
Sponsor: Hanoi Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Zap to see: electrical therapy for eye disease
Symptom relief OngoingThis study tests a treatment called transcorneal electrical stimulation to see if it can improve vision in people with retinitis pigmentosa, an eye disease that causes vision loss. Twenty-one adults with the condition received the therapy, and researchers measured changes in thei…
Sponsor: Nova Southeastern University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy may offer relief for chronic watery eyes
Symptom relief OngoingThis study compares using an anti-inflammatory eye drop (nepafenac) plus a lubricant versus a lubricant alone to treat watery eyes (epiphora) caused by narrowing of the tear duct opening. Researchers will measure changes in tear duct size and symptom severity in 68 Mexican adults…
Phase 4 • Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New program aims to ease burden on families of kids with rare diseases
Symptom relief By invitation onlyThis study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …
Sponsor: Children's National Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Light mask may soothe dry eyes in Graves' patients
Symptom relief By invitation onlyThis study tests a low-level light therapy mask for dry eye disease in people with Graves' eye disease who haven't improved with standard treatments. Thirty adults will receive either the real light therapy or a sham device. The goal is to see if the treatment improves tear film …
Sponsor: Grigore T. Popa University of Medicine and Pharmacy • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New eye drop aims to zap dry eye discomfort in weeks
Symptom relief By invitation onlyThis study tests whether Acoltremon 0.003% eye drops can quickly relieve symptoms like burning, irritation, and blurriness in people with moderate-to-severe dry eye disease. Fifty adults will use the drops as directed and report their symptom changes over 28 days. The goal is to …
Sponsor: Colvard Kandavel Eye Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Remote nurse coaching boosts cataract recovery, study suggests
Symptom relief OngoingThis study tests whether extra support from a nurse via phone calls and text messages helps patients stick to their eye drop schedule and feel more satisfied after cataract surgery. About 128 adults having cataract surgery for the first time will be split into two groups: one get…
Sponsor: Züleyha Sönmez • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Could a light mask ease dry eye in kids?
Symptom relief By invitation onlyThis study tests a red-light mask (low-level light therapy) for treating dry eye and meibomian gland disease in 15 children with severe symptoms. It compares the light mask to standard care (warm compresses and artificial tears). The goal is to see if the light mask improves glan…
Sponsor: Illinois College of Optometry • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Which contact lens gives sharper vision? new study puts two brands to the test
Symptom relief OngoingThis study compares how well two types of daily disposable multifocal contact lenses work for people with nearsightedness (myopia). Researchers will measure things like sharpness of vision, reading ability, and eye coordination. About 30 people aged 9 to 30 who already wear conta…
Sponsor: Visioneering Technologies, Inc • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Menthol vapors may replace eye drops for dry eyes
Symptom relief By invitation onlyThis study tests whether applying menthol solution to the cheek can release vapors that stimulate cold sensors on the eye, triggering natural tear production. Thirty healthy adults will receive either menthol or a placebo on one cheek, and researchers will measure if tears overfl…
Phase 2 • Sponsor: Reinhold Vieth • Aim: Symptom relief
Last updated Jun 26, 2026 17:32 UTC
-
Allergy drops under the microscope: do they really make life better for itchy eyes?
Symptom relief OngoingThis observational study looks at 100 patients with allergic conjunctivitis who received sublingual (under-the-tongue) allergen immunotherapy. Researchers will track changes in symptoms and quality of life using a standard questionnaire over 6 months. The goal is to see if this t…
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Symptom relief
Last updated Jun 26, 2026 14:24 UTC
-
Could a tiny corneal implant replace reading glasses?
Symptom relief OngoingThis study tests a new device called CorVision, a tiny lens made from collagen that is placed inside the cornea to improve near vision in people with presbyopia (age-related difficulty seeing up close). 110 adults aged 40-65 will receive the implant in one eye through a minimally…
Sponsor: LinkoCare Life Sciences AB • Aim: Symptom relief
Last updated Jun 26, 2026 12:33 UTC
-
Scientists track eye disease progression over five years
Knowledge-focused OngoingThis study follows 110 people who previously took part in the AREDS or AREDS2 trials to see how age-related macular degeneration (AMD) and cataracts change over time. Participants get a yearly eye exam, including vision tests and eye photos, and may give a blood sample. The goal …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Could an algorithm replace the eye chart? a trial puts software-guided refraction to the test.
Knowledge-focused OngoingThis study tests whether a software program called the Vision Trainer can guide eyeglass prescriptions as accurately as the traditional manual method performed by trained examiners. Adults with myopia (nearsightedness) will have their prescriptions determined both ways, and the r…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches major study to unravel mysteries of rare genetic diseases
Knowledge-focused By invitation onlyThis study aims to identify genetic, biochemical, and clinical factors linked to disease severity in people with Gaucher disease and other lysosomal storage disorders. Researchers will evaluate up to 1,000 participants, including patients, carriers, and healthy controls, to bette…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Eye disease progression under the microscope: 3-Year study launched
Knowledge-focused OngoingThis study follows 400 people with intermediate age-related macular degeneration (AMD) for about 3 years. Researchers watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disease. No…
Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Which Mini-Implant size works best? new study aims to find out
Knowledge-focused OngoingThis study tests two different diameters (1.6mm and 2mm) of mini-implants placed in the upper jaw to support orthodontic tooth movement. Twenty people receiving braces will get one size on each side of their mouth. Researchers will measure how stable the implants are, how much pa…
Sponsor: University of Baghdad • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Eye cancer survivors: does treatment choice impact Long-Term happiness?
Knowledge-focused By invitation onlyThis study looks at children and teens who survived retinoblastoma in one eye. Researchers want to see if those who had chemotherapy injected into the eye artery have a different quality of life than those who had the eye removed. Participants and their parents will fill out surv…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Hidden muscle loss in Sjögren's syndrome: a new study looks for answers
Knowledge-focused OngoingThis study examines whether women with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth, also experience muscle loss, a condition called sarcopenia. Researchers will measure muscle strength, muscle mass, and physical performance in 120 participants…
Sponsor: Antalya Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can eye surgery restore blood flow in glaucoma?
Knowledge-focused OngoingResearchers are studying whether lowering the pressure inside the eye improves blood flow to the eye in people with glaucoma. The study follows adults with open-angle or chronic angle-closure glaucoma who are scheduled for glaucoma surgery. Using imaging scans, the team measures …
Sponsor: Oregon Health and Science University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Massive Real-World study tracks roche eye drugs in 6,000 patients
Knowledge-focused OngoingThis study is collecting long-term, real-world data from about 6,000 adults being treated with Roche eye medications (Faricimab or the Port Delivery System with Ranibizumab) for conditions like wet age-related macular degeneration and diabetic macular edema. The goal is to unders…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
New eye imaging could reveal hidden clues to vision loss
Knowledge-focused By invitation onlyThis study explores whether combining three eye-imaging techniques can reveal how structural damage in the retina relates to vision loss in people with geographic atrophy, a form of age-related macular degeneration. Researchers will use OCT scans, ultra-high-resolution AOSLO imag…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists track rare eye disease to prepare for future treatments
Knowledge-focused OngoingThis study follows 68 people aged 12 and older who have ABCA4 gene mutations, which can cause vision loss from diseases like Stargardt disease. Over 10 years, researchers will collect blood and skin samples and perform detailed eye exams to understand how the disease progresses. …
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Kidney clues may predict eye swelling after cataract surgery in diabetes patients
Knowledge-focused OngoingThis study looks at whether diabetic kidney disease and blood-sugar control before surgery can help predict a common complication called pseudophakic macular edema (PME) — swelling of the central retina — after cataract surgery in people with type 2 diabetes. Researchers will rev…
Sponsor: Thammasat University Hospital • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
AI eye scan predicts treatment shifts for diabetic macular edema
Knowledge-focused CancelledThis study will use artificial intelligence (AI) to analyze eye scans from 554 adults with diabetic macular edema (DME). The goal is to see if AI can predict when a person's eye treatment needs to change. Participants will not receive any new treatment; instead, researchers will …
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Eye scanner software update put to the test
Knowledge-focused OngoingThis study compares a new software version (1.5) of the ANTERION eye imaging device against the older cleared version (1.2.4). Researchers will check if the new software gives consistent and accurate measurements of eye structures like cornea thickness and lens thickness. The stu…
Sponsor: Heidelberg Engineering GmbH • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
New blood test could spot autoimmune diseases earlier
Knowledge-focused By invitation onlyThis study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Fatigue study seeks to unravel mystery of exhaustion
Knowledge-focused OngoingThis study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …
Sponsor: National Center for Complementary and Integrative Health (NCCIH) • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
5-Minute MRI could spot brain changes in rare disorder
Knowledge-focused OngoingThis study tests a new, fast MRI method that takes about 5 minutes, uses no contrast dye, and often no sedation, even in children. Researchers will scan 80 people with Sturge-Weber syndrome (ages 3 months to 30 years) to see if this quick MRI can accurately detect brain abnormali…
Sponsor: Wayne State University • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Researchers track Long-Term safety of experimental eye cancer treatment
Knowledge-focused By invitation onlyThis study is a long-term follow-up for 100 people who completed a previous trial of bel-sar, an experimental treatment for early choroidal melanoma (a type of eye cancer). Participants will not receive any new treatment but will be monitored for about 5 more years to check for s…
Sponsor: Aura Biosciences • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Scientists track rare eye disease to uncover clues for future treatments
Knowledge-focused OngoingThis study follows 46 people with gyrate atrophy, a rare genetic condition that causes vision loss, over 4 years. Researchers measure ornithine levels in the blood and track changes in the retina using eye scans and photos. The goal is to learn how the disease progresses under st…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can tracking a rare eye cancer pave the way for new treatments?
Knowledge-focused OngoingThis study follows people diagnosed with uveal melanoma, a rare eye cancer, over time to document the disease's natural course. Researchers will collect data on how the cancer progresses, including survival rates and whether it spreads. The goal is to build a detailed registry th…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Eye disease study aims to pave way for future treatments
Knowledge-focused OngoingThis study follows 127 people with a genetic eye condition called USH2A-related retinal degeneration, which can cause vision loss and hearing problems. Researchers measure changes in vision, retinal sensitivity, and mobility over several years. The goal is to understand how the d…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Glaucoma surgery checked 5 years later: does it hold up?
Knowledge-focused By invitation onlyThis study follows 250 people with open-angle glaucoma who had a new type of surgery called CycloPen, which aims to improve fluid drainage from the eye. Researchers will measure eye pressure at 3, 4, and 5 years after surgery to see if the benefits last. The goal is to understand…
Sponsor: Iantrek, Inc. • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Eye-Opening study: why do some Kids' contact lenses work better for nearsightedness?
Knowledge-focused OngoingThis study examines protein differences in the tears of nearsighted children who use special overnight contact lenses (orthokeratology) to slow down worsening vision. Researchers want to understand why some children get better control of their myopia than others. The study involv…
Sponsor: Vejle Hospital • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Eye scans could spot Diabetes-Related vision damage years early
Knowledge-focused OngoingThis study uses a non-invasive eye scan called OCTA to examine tiny blood vessels in the retina of adults with type 1 diabetes. The goal is to detect early signs of diabetic retinopathy, a leading cause of vision loss, before symptoms appear. Researchers will measure vessel densi…
Sponsor: University of Athens • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
AI eye scans aim to predict Sight-Threatening complication after retinal surgery
Knowledge-focused By invitation onlyThis study investigates whether advanced eye imaging and artificial intelligence can predict proliferative vitreoretinopathy (PVR), a condition that can cause retinal detachment surgery to fail. Researchers will analyze scans from 100 patients with retinal detachment, some with P…
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Eye surgery silicone may change cornea cells, study finds
Knowledge-focused OngoingThis study looks at how silicone oil, used to repair detached retinas, affects the cells on the inner surface of the cornea. Researchers will measure cell density and shape changes in 40 patients at 1 and 3 months after surgery. They also want to see if any changes go away after …
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Withdrawn study sought better way to time eye injections
Knowledge-focused CancelledThis study aimed to see if how well a person can fix their gaze relates to signs of active disease on eye scans in patients with age-related macular degeneration (ARMD) treated with antiVEGF injections. Researchers planned to follow patients for two years, measuring fixation qual…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists track Long-Term safety of experimental AMD therapy
Knowledge-focused By invitation onlyThis study follows people with advanced dry age-related macular degeneration who previously received a one-time injection of the experimental treatment VOY-101. Researchers are monitoring participants over the long term to check for any side effects related to the treatment. The …
Sponsor: Perceive Biotherapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study tracks stargardt disease to pave way for future treatments
Knowledge-focused OngoingThis study follows 80 people aged 8 to 50 with Stargardt disease, a genetic eye condition that causes vision loss. Researchers will monitor how the disease changes over time using eye imaging. The goal is to better understand the disease and prepare for future clinical trials.
Sponsor: AAVantgarde Bio Srl • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Eye drop study reveals hidden changes in eye bacteria
Knowledge-focused OngoingThis study looks at how a common glaucoma eye drop (latanoprost with preservatives) changes the natural bacteria living on the eye's surface. Researchers will compare the eye bacteria of 45 newly diagnosed glaucoma patients before and after at least 6 months of treatment. The goa…
Sponsor: University of Ioannina • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Eye strain test may forecast glaucoma course
Knowledge-focused OngoingThis study looks at whether images of the optic nerve head taken at two different eye pressures can predict how glaucoma will change over time. Researchers will compare these strain measurements to actual vision loss in 130 glaucoma patients. The goal is to develop a new biomarke…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive italian MS registry aims to unlock secrets of the disease
Knowledge-focused By invitation onlyThis observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…
Sponsor: Fondazione Italiana Sclerosi Multipla • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Ground-Level vision test could help retinitis pigmentosa patients walk better
Knowledge-focused CancelledThis study was designed to see if a new method of measuring the visual field—by projecting vision zones on the ground—helps people with retinitis pigmentosa understand their remaining sight and improve their walking rehabilitation. The trial was withdrawn before enrolling any par…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Major study on rare childhood liver diseases halted
Knowledge-focused PausedThis study followed children and young adults with genetic liver diseases that cause bile buildup. The goal was to track how these diseases progress over time, including the need for liver transplants or other complications. No treatments were tested; the aim was simply to learn …
Sponsor: Arbor Research Collaborative for Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Which reading glasses give the best view? new study puts three lens designs to the test
Knowledge-focused OngoingThis study compares three types of progressive lenses to see which provides the widest clear vision at distances from 4 meters down to 25 centimeters. About 26 presbyopic participants will test each lens in a random, double-blind order. The goal is to help eye doctors choose the …
Sponsor: University of Seville • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to tackle vision problems in upper manhattan
Knowledge-focused CancelledThis study aims to help adults aged 40 and older in Upper Manhattan get better eye care. It will offer free eye screenings at local health centers and senior centers, and provide support like scheduling appointments and transportation. The goal is to see if this extra help leads …
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive genetic study aims to unlock secrets of rare metabolic diseases
Knowledge-focused By invitation onlyThis study will collect and analyze genetic data from 1000 people with suspected inherited metabolic diseases, including conditions like epilepsy and mitochondrial disorders. Researchers at Karolinska University Hospital aim to improve diagnosis by using advanced genetic testing …
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Eggs on the menu: could a daily dozen slow vision loss?
Knowledge-focused OngoingThis pilot study tests whether older adults with intermediate age-related macular degeneration (AMD) can eat 2 or 4 whole eggs daily for 5 months. The main goal is to see if people can stick with the diet, not to prove eggs improve vision. Researchers will also measure changes in…
Early phase 1 • Sponsor: Kathryn Starr • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Researchers track Long-Term safety of experimental eye cancer drug
Knowledge-focused OngoingThis registry follows 63 patients with choroidal melanoma or early eye lesions who were treated with the experimental drug bel-sar in earlier studies. The goal is to monitor long-term safety, side effects, and any spread of the disease over time. Participants are not receiving ne…
Sponsor: Aura Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Diabetes drug eye risk under microscope
Knowledge-focused OngoingThis study looks at how newer diabetes medications (SGLT2 inhibitors and GLP-1 receptor agonists) affect the eyes of people with type 2 diabetes. Researchers will monitor 40 adults who take metformin and are starting these newer drugs. The goal is to see if these drugs cause any …
Sponsor: University of Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Rural clinics get help to catch diabetic eye disease early
Knowledge-focused By invitation onlyThis study looks at whether a program called I-SITE can help rural health clinics use teleophthalmology (remote eye exams) to screen more diabetic patients for eye problems. Up to 10 health systems and 10,000 patients will take part. The goal is to see if screening rates improve …
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Special lens may slow nearsightedness – tiny study looks at how
Knowledge-focused OngoingThis study looks at how a new type of eyeglass lens affects the back layer of the eye (the choroid) in children with worsening nearsightedness. Ten children already in a larger study will have their eye thickness measured with a special camera. The goal is to understand if the le…
Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Sjögren's study dives deep into immune clues in spit and blood
Knowledge-focused OngoingThis study looks at immune system markers in the saliva and blood of 80 people with primary Sjögren's syndrome, a chronic disease causing dry eyes and mouth. Researchers will check for antibodies that may block a key enzyme and see how gum disease affects symptoms. The goal is to…
Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New glasses for nearsighted kids put to the test
Knowledge-focused OngoingThis study looks at how well children with nearsightedness (myopia) see when wearing special glasses. The 51 participants are already part of a larger study on myopia progression. Researchers will measure reading speed and vision in different lighting to see how the lenses perfor…
Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
10,000 people to have eye and skin pigments measured in nutrition study
Knowledge-focused By invitation onlyThis study aims to understand how diet affects the eyes and skin by measuring natural pigments called carotenoids. Researchers will use non-invasive methods to check levels in the eye and skin, and also test blood in some participants. Anyone age 7 or older having a routine eye e…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Do special glasses keep working after kids stop wearing them?
Knowledge-focused OngoingThis study follows 90 children who previously wore special spectacle lenses to slow nearsightedness (myopia). After stopping the lenses, researchers measure how much their vision changes over 12 months. The goal is to see if the benefits of the lenses last after use ends.
Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New eye tests could speed up retinitis pigmentosa treatment trials
Knowledge-focused OngoingThis study aims to find better ways to measure how retinitis pigmentosa (a genetic eye disease that causes vision loss) progresses over time. Researchers will use advanced imaging and vision tests in 40 people with specific genetic forms of the disease. The goal is to identify re…
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New glasses tested to see how Kids' eyes focus
Knowledge-focused OngoingThis study looks at how the eye focuses (lag of accommodation) when children with nearsightedness wear special DOT pattern spectacle lenses compared to regular glasses. About 30 kids aged 6 to 18 will have their vision measured at distance and close-up with each lens type. The go…
Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New lenses may reveal how to slow nearsightedness in kids
Knowledge-focused OngoingThis study tests whether special spectacle lenses called Diffusion Optics Technology (DOT) lenses can change the thickness of the choroid, a layer of blood vessels in the eye. Researchers will measure these changes in 30 children aged 8-14 with normal vision after wearing the len…
Sponsor: SightGlass Vision, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Why do some blind people see things that Aren't there? new study aims to find out
Knowledge-focused By invitation onlyThis study looks at how common Charles Bonnet Syndrome (CBS) is in people with vision loss from conditions like macular degeneration or glaucoma. CBS causes complex visual hallucinations without mental illness. Researchers will survey 640 participants to measure how often it happ…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Eye fluid test could spot dry AMD changes early
Knowledge-focused OngoingThis study is testing whether taking a tiny sample of fluid from the front of the eye is safe for people with dry age-related macular degeneration (AMD). Researchers will analyze proteins in the fluid to see if they change over time. The study includes 50 adults aged 50 to 89, so…
Sponsor: ClinOmicsAI • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Scientists hunt for clues to ichthyosis in skin and blood
Knowledge-focused By invitation onlyThis study looks at skin and blood samples from 200 people with ichthyosis (a genetic condition causing dry, scaly skin) and healthy volunteers. Researchers want to find specific markers that could help them understand the disease better and develop new treatments. No treatment i…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
AI predicts hidden glaucoma risk after LASIK in 10,000-Patient study
Knowledge-focused OngoingThis study uses artificial intelligence to predict true eye pressure after corneal refractive surgery like LASIK or SMILE. Standard eye pressure measurements can be falsely low after these surgeries, masking glaucoma risk. Researchers will analyze data from over 10,000 participan…
Sponsor: Tianjin Eye Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study tracks rare disease MLIV to map its natural course
Knowledge-focused OngoingThis study looks back at medical records of 50 people with Mucolipidosis Type IV (MLIV) to learn how the disease typically progresses. Researchers want to know when children reach or lose developmental milestones, how their movement and vision change, and what lab results look li…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
500 eye melanoma patients share their quality of life journey
Knowledge-focused OngoingThis study follows 500 people diagnosed with uveal melanoma (a rare eye cancer) for five years after treatment. Participants fill out questionnaires about their physical and mental well-being, treatment side effects, and decision-making. The goal is to learn how different treatme…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists track vision loss in rare genetic eye disease to pave way for future treatments
Knowledge-focused OngoingThis study follows 50 people with a rare inherited eye condition called PRPF31-related retinal dystrophy (RP11) to see how their vision changes over time. Researchers will measure things like visual acuity, retinal thickness, and quality of life using eye exams and questionnaires…
Sponsor: PYC Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Robot eye scanner study pulled before it started
Knowledge-focused CancelledThis study planned to test a new robotic system that helps take detailed 3D images of the far edges of the retina, an area that is hard to see with standard eye scanners. The goal was to see if the robot could make imaging easier and more comfortable for healthy adults. However, …
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Can we predict heart disease in kids? new study seeks answers
Knowledge-focused OngoingThis study looks at over 1,000 South African children ages 5 to 9 to understand why some develop early signs of high blood pressure and heart problems. Researchers will measure blood pressure, body fat, and fitness, and test blood for early warning markers. The goal is to find wa…
Sponsor: North-West University, South Africa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Could your phone replace a Post-Surgery eye check?
Knowledge-focused By invitation onlyThis study tests whether a smartphone app (WHOeyes) plus a symptom questionnaire can safely replace the standard in-clinic checkup one week after cataract surgery. About 334 people aged 50–80 with uncomplicated cataracts will either use the app at home or come to the clinic. The …
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Eye fluid analysis may unlock secrets of rare eye condition
Knowledge-focused OngoingThis pilot study examines proteins in the vitreous (the gel-like fluid inside the eye) of patients with pseudoexfoliation syndrome (PEX), a condition that can lead to glaucoma. Researchers will compare protein levels between eyes with and without PEX in 24 adults undergoing eye s…
Sponsor: Prim. Prof. Dr. Oliver Findl, MBA • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Premature Babies' vision tracked years after ROP treatment
Knowledge-focused OngoingThis study follows about 100 premature babies who were treated for retinopathy of prematurity (ROP) in an earlier study. Researchers will check their eyesight and overall development over time to see how they are doing. No new treatment is given in this study.
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused CancelledThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Cataract surgery tech showdown: laser vs standard handpieces
Knowledge-focused CancelledThis study was designed to compare two newer technologies for cataract surgery: a femtosecond laser and a special handpiece that monitors eye pressure. The goal was to see if these tools cause less damage to the cornea and use less energy than standard methods. However, the study…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Eye pressure clue could sharpen vision after retinal surgery
Knowledge-focused OngoingThis study looks at whether having low eye pressure before surgery changes how well doctors can predict your final glasses prescription after a combined cataract and retinal detachment repair. Researchers will compare two groups of people: those with low eye pressure and those wi…
Sponsor: Kazakh Eye Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Tear test could spot eye disease risk in thyroid patients
Knowledge-focused OngoingThis research study aims to create a simple, non-invasive test using tears and blood to predict which patients with hyperthyroidism are at risk of developing Graves' Orbitopathy (eye disease). Researchers will analyze samples from 90 participants, including healthy controls and t…
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Massive diabetes biobank aims to predict kidney and heart risks
Knowledge-focused OngoingThis study is building a large biobank of health information and blood samples from 48,000 people with diabetes in Hong Kong. Researchers will analyze genetic and other markers to find better ways to predict serious complications like kidney failure, heart disease, and stroke. Th…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Eye tests may predict vision after corneal transplant
Knowledge-focused OngoingThis study looks at how keratoconus, a disease that thins and bulges the cornea, affects electrical signals in the eye and brain. Researchers will measure these signals in 50 adults with different stages of keratoconus using standard eye tests. The goal is to see if these measure…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New national registry aims to improve care for rare genetic polyposis syndromes
Knowledge-focused OngoingThis study is a national registry collecting data from 1500 people with familial adenomatous polyposis (FAP) and related conditions across 28 Italian centers. It aims to better understand how these diseases progress, how they are currently managed, and what factors influence outc…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New eye software could sharpen inflammation detection
Knowledge-focused OngoingThis study is testing a new software that measures eye inflammation from standard images taken during routine care. Researchers will enroll 50 people with uveitis, an inflammatory eye disease, to see if the software can detect meaningful changes in inflammation. The goal is to he…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New study seeks clues to rare brain disorder
Knowledge-focused OngoingThis study looks at 600 people with Sturge-Weber syndrome, a rare condition that affects the brain and skin. Researchers want to find out what causes the disease to get worse over time. They will study genes, blood vessel changes, and substances in urine to better predict and man…
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Eye scans reveal how well glaucoma stents are placed
Knowledge-focused OngoingThis study looks at 116 adults who had glaucoma stent surgery up to 2 years ago. Researchers use a special eye scan (OCT) to check if the tiny stents are in the right position and how that affects eye pressure. The goal is to learn how often stents are misplaced and whether prope…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Does donor diabetes impact corneal transplant outcomes?
Knowledge-focused By invitation onlyThis study looks at whether corneas from donors with diabetes work as well as those from donors without diabetes after a specific type of corneal transplant called DMEK. Researchers will track 570 participants for 5 years to measure cell loss and overall transplant success. The g…
Sponsor: Case Western Reserve University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New scanner could help surgeons predict cataract hardness
Knowledge-focused OngoingThis study tests a special scanning device that measures how stiff the eye's lens is in people with cataracts. Researchers want to see if this stiffness measurement matches standard cataract grading and surgery energy needed. 50 adults with cataracts will be scanned before surger…
Sponsor: Prim. Prof. Dr. Oliver Findl, MBA • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Healthy volunteers help unlock secrets of vision recovery
Knowledge-focused OngoingThis study looks at how the brain changes and adapts after losing central vision, which happens in conditions like macular degeneration. Researchers are testing different training tasks in 120 healthy adults aged 18-30 to measure improvements in eye movements and focus. The goal …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can less radiation treat eye cancer just as well?
Knowledge-focused OngoingThis study tracks 42 people with ocular melanoma who received radiation therapy via eye plaque brachytherapy. Researchers want to see if using lower radiation doses can still keep the cancer from coming back while reducing harmful side effects. The goal is to find the safest effe…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Tear and blood molecules may unlock secrets of eye allergies
Knowledge-focused OngoingThis study compares small molecules called microRNAs in the tears and blood of 40 people with allergic conjunctivitis versus healthy individuals. The goal is to find patterns that could help diagnose the condition and reveal new targets for treatment. Participants are aged 5 to 3…
Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Scientists map rare blindness to speed future cures
Knowledge-focused OngoingThis study follows 44 people with a rare genetic form of Usher syndrome caused by PCDH15 mutations. Over 48 months, researchers measure how their vision changes using eye exams and imaging. The goal is to identify the best ways to track disease progression, which will help design…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Eye pain mystery: scientists probe nerve link in dry eye sufferers
Knowledge-focused PausedThis study looks at how common nerve problems are in people who feel eye discomfort. Researchers will test 1,000 participants to see if their pain is linked to nerve damage rather than just dry eye. The goal is to better understand these conditions and improve diagnosis.
Sponsor: Tufts Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Can blood stem cells predict diabetic eye disease?
Knowledge-focused OngoingThis study looks at blood stem cells (called EPCs) in people with and without diabetes to see if they work differently. Researchers want to know if these cells can predict diabetic retinopathy, an eye disease that can cause vision loss. The study involves 78 adults, including 39 …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New 3D-CT model could help doctors safely manage airways in infants with rare facial condition
Knowledge-focused OngoingThis study is developing a prediction tool using 3D-CT scans to identify which infants with Pierre Robin sequence (a condition with a small jaw and tongue that can block the airway) are likely to have a difficult time during breathing tube placement for surgery. Researchers will …
Sponsor: Nanjing Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Eye fluid test may personalize uveitis treatment
Knowledge-focused OngoingThis study tests whether analyzing fluid from the eye can predict which immunosuppressive drug will work best for people with non-infectious uveitis, an eye inflammation condition. About 220 participants who haven't responded well to steroids will provide eye fluid and blood samp…
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Eye cancer survivors: does anesthesia affect the brain?
Knowledge-focused By invitation onlyThis study looks at how cancer treatment and multiple rounds of anesthesia affect thinking skills, emotions, and quality of life in people who survived retinoblastoma (a rare eye cancer) or were at risk for it. Researchers will test memory, attention, and other brain functions in…
Sponsor: Amsterdam University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Child cataract surgery study canceled before starting
Knowledge-focused CancelledThis study planned to observe different surgical approaches for children with cataracts, focusing on implant types and surgery timing. It was withdrawn before enrolling any participants, so no information was collected. The goal was to understand which strategies work best for yo…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Gut leak link to Sjögren's Flare-Ups under microscope
Knowledge-focused OngoingThis study looks at whether changes in gut bacteria can affect Sjögren's syndrome, an autoimmune disease causing dry eyes, dry mouth, and fatigue. Researchers will measure blood markers of gut leakage in 50 adults with Sjögren's to see if these markers change when disease activit…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
AI learns from healthy eyes to spot glaucoma earlier
Knowledge-focused OngoingThis study gathers vision data from 100 healthy adults to teach an AI system how normal eyes see. The goal is to make a new eye test that can find problems like glaucoma more accurately. Participants do not receive any treatment, and the results will help improve future diagnosis…
Sponsor: Sight Intelligence Engineering Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New study tests if help with housing, food, or transport can cut missed arthritis appointments
Knowledge-focused OngoingThis study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Genetic clues to childhood obesity: study seeks answers
Knowledge-focused OngoingThis study looks at the genes of 1000 people with severe early-onset obesity to find rare genetic causes. It focuses on conditions like Bardet-Biedl syndrome. The goal is to better understand these conditions and improve how they are diagnosed. Participants provide a blood or sal…
Sponsor: Rolfs Consulting und Verwaltungs-GmbH (RCV) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Can your diet and habits protect your eyes? new study investigates AMD risk factors
Knowledge-focused OngoingThis study is looking at how genetics, diet, lifestyle, and medications work together to influence the risk of age-related macular degeneration (AMD), a leading cause of vision loss. Researchers will collect blood samples and health information from 1,800 adults in Portugal. The …
Sponsor: Association for Innovation and Biomedical Research on Light and Image • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New algorithm aims to catch ovarian damage early in young cancer survivors
Knowledge-focused CancelledThis study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC
-
Eye lens implant safety study pulled before starting
Knowledge-focused CancelledThis study was designed to check the long-term safety and performance of AcrySof IQ Vivity lens implants in people who had them in both eyes for 3 to 5 years. It was a real-world observation, not a treatment test. However, the study was withdrawn before enrolling any participants…
Sponsor: Alcon Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:27 UTC
-
Can yearly MRIs catch second cancers in retinoblastoma survivors?
Knowledge-focused OngoingThis study looks at whether yearly MRI scans can find new head and neck or brain cancers early in people who had hereditary retinoblastoma and were treated with radiation. Researchers will follow 88 participants for 10 years to see if early detection leads to better surgery outco…
Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:56 UTC
-
New eye test could spot Blindness-Causing diseases years earlier
Knowledge-focused By invitation onlyThis study is testing a special eye test called microperimetry to see if it can detect early signs of dry age-related macular degeneration and diabetic retinopathy. Researchers will measure how sensitive the central retina is to light and compare it with standard scans. The goal …
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:41 UTC